CN112142818A - 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 - Google Patents
齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 Download PDFInfo
- Publication number
- CN112142818A CN112142818A CN201910572404.0A CN201910572404A CN112142818A CN 112142818 A CN112142818 A CN 112142818A CN 201910572404 A CN201910572404 A CN 201910572404A CN 112142818 A CN112142818 A CN 112142818A
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- 300mhz
- nmr
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 44
- 229940100243 oleanolic acid Drugs 0.000 title abstract description 32
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title abstract description 28
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title abstract description 28
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title abstract description 28
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 577
- -1 pentacyclic triterpenoid compound Chemical class 0.000 claims abstract description 159
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 239000000556 agonist Substances 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000026731 phosphorylation Effects 0.000 claims abstract description 13
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 claims abstract description 6
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims abstract 12
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims abstract 12
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 16
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 15
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 13
- HWWPLBWGSPKLOL-UHFFFAOYSA-N diethylamino(trimethyl)azanium Chemical compound CCN(CC)[N+](C)(C)C HWWPLBWGSPKLOL-UHFFFAOYSA-N 0.000 claims description 12
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000037921 secondary disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000033386 Buerger disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010011763 Cystic fibrosis lung Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000032859 Synucleinopathies Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 3
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 206010021198 ichthyosis Diseases 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000001297 phlebitis Diseases 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 201000004595 synovitis Diseases 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 208000032274 Encephalopathy Diseases 0.000 claims description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000002033 Myoclonus Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 abstract description 9
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 abstract description 9
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 294
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 268
- 238000005160 1H NMR spectroscopy Methods 0.000 description 184
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 181
- 238000000034 method Methods 0.000 description 173
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 165
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- 238000006243 chemical reaction Methods 0.000 description 143
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- 239000007787 solid Substances 0.000 description 76
- 239000000706 filtrate Substances 0.000 description 68
- 238000001514 detection method Methods 0.000 description 59
- 238000010898 silica gel chromatography Methods 0.000 description 57
- 239000000243 solution Substances 0.000 description 54
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 50
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 49
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 33
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 32
- 239000002253 acid Substances 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 28
- 239000011734 sodium Substances 0.000 description 25
- 238000003756 stirring Methods 0.000 description 25
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 24
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 239000010410 layer Substances 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 17
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 15
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- DAKZISABEDGGSV-UHFFFAOYSA-N n-(2-aminoethyl)acetamide Chemical compound CC(=O)NCCN DAKZISABEDGGSV-UHFFFAOYSA-N 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 238000000967 suction filtration Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 11
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 11
- 229910021641 deionized water Inorganic materials 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 9
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 9
- NICIHZYGEQHDPN-UHFFFAOYSA-N 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanamine Chemical compound NCCN1CCS(=O)(=O)CC1 NICIHZYGEQHDPN-UHFFFAOYSA-N 0.000 description 9
- FSRMWCVZAUEPEQ-UHFFFAOYSA-N 3-(1,1-dioxo-1,4-thiazinan-4-yl)propan-1-amine Chemical compound NCCCN1CCS(=O)(=O)CC1 FSRMWCVZAUEPEQ-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000012964 benzotriazole Substances 0.000 description 8
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000011664 nicotinic acid Substances 0.000 description 8
- 229960003512 nicotinic acid Drugs 0.000 description 8
- 235000001968 nicotinic acid Nutrition 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 7
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 6
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 5
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 5
- GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 5
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 5
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 5
- 108010018763 Biotin carboxylase Proteins 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 4
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 4
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 4
- VPBWZBGZWHDNKL-UHFFFAOYSA-N 3-pyrrolidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCC1 VPBWZBGZWHDNKL-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- NEDMOHHWRPHBAL-RFVHGSKJSA-N benzyl (2r)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.O=C([C@@H]1NCCC1)OCC1=CC=CC=C1 NEDMOHHWRPHBAL-RFVHGSKJSA-N 0.000 description 4
- NEDMOHHWRPHBAL-MERQFXBCSA-N benzyl (2s)-pyrrolidin-1-ium-2-carboxylate;chloride Chemical compound Cl.O=C([C@H]1NCCC1)OCC1=CC=CC=C1 NEDMOHHWRPHBAL-MERQFXBCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- AVPAYFOQPGPSCC-UHFFFAOYSA-N 3-methoxyazetidine Chemical compound COC1CNC1 AVPAYFOQPGPSCC-UHFFFAOYSA-N 0.000 description 3
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 3
- 230000007783 downstream signaling Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 2
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 2
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 2
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical group C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- CYOIAXUAIXVWMU-UHFFFAOYSA-N 2-[2-aminoethyl(2-hydroxyethyl)amino]ethanol Chemical compound NCCN(CCO)CCO CYOIAXUAIXVWMU-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- JMUCXULQKPWSTJ-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-amine Chemical group NCCCN1CCCCC1 JMUCXULQKPWSTJ-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical group O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108700042658 GAP-43 Proteins 0.000 description 2
- 108700032487 GAP-43-3 Proteins 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 2
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 2
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 229960005215 dichloroacetic acid Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 2
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical group OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 108091008762 thyroid hormone receptors ß Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HMUMWSORCUWQJO-QAPCUYQASA-N (2s)-2-[3-(2-chlorophenoxy)-5-oxo-2h-pyrrol-1-yl]-n-[1-[(2r)-2,3-dihydroxypropyl]pyrazol-3-yl]-4-methylpentanamide Chemical compound C=1C(=O)N([C@@H](CC(C)C)C(=O)NC2=NN(C[C@@H](O)CO)C=C2)CC=1OC1=CC=CC=C1Cl HMUMWSORCUWQJO-QAPCUYQASA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 1
- SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SJKLCUGQVVYDCX-HRNVLBFRSA-N 1-(4-tert-butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea Chemical compound CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCNC(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 SJKLCUGQVVYDCX-HRNVLBFRSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- HNZJIWIXRPBFAN-UHFFFAOYSA-N 1-cyclopropylpiperazine Chemical compound C1CC1N1CCNCC1 HNZJIWIXRPBFAN-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- WJVAPEMLIPHCJB-UHFFFAOYSA-N 1-n-methylpropane-1,2-diamine Chemical group CNCC(C)N WJVAPEMLIPHCJB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KZSKGLFYQAYZCO-UHFFFAOYSA-N 2-[3-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(N2CC(O)(C2)C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)Cl)=C1 KZSKGLFYQAYZCO-UHFFFAOYSA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- UGHOJWLZPSTTKB-UHFFFAOYSA-N 4-(2-bromoethyl)morpholine;hydrobromide Chemical compound Br.BrCCN1CCOCC1 UGHOJWLZPSTTKB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OQDQIFQRNZIEEJ-UHFFFAOYSA-N 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid Chemical compound C1=C2N=CSC2=CC(S(=O)(=O)N2C3=CC=C(Cl)C=C3C=C2CCCC(=O)O)=C1 OQDQIFQRNZIEEJ-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 description 1
- DIEMCUFYSOEIDU-UHFFFAOYSA-N 6-fluoropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(F)=N1 DIEMCUFYSOEIDU-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 description 1
- 229940125827 GPR40 agonist Drugs 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 description 1
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- IXXFMUREDLOFNU-UHFFFAOYSA-N N1CCS(CC1)(=O)=O.N1CCOCC1 Chemical compound N1CCS(CC1)(=O)=O.N1CCOCC1 IXXFMUREDLOFNU-UHFFFAOYSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- VYLOOGHLKSNNEK-PIIMJCKOSA-N OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 Chemical compound OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 VYLOOGHLKSNNEK-PIIMJCKOSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ULVBLFBUTQMAGZ-RTNCXNSASA-N [(2r,3r,4s,5r,6r)-6-[[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-5-yl]phenyl]carbamoylamino]-3,5-dihydroxy-4-phenylmethoxyoxan-2-yl]methyl hydrogen sulfate Chemical compound O([C@H]1[C@H](O)[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]1O)NC(=O)NC=1C=CC=C(C=1)[C@@H]1C2=CC(=CC=C2S(=O)(=O)C[C@@]([C@@H]1O)(CC)CCCC)N(C)C)CC1=CC=CC=C1 ULVBLFBUTQMAGZ-RTNCXNSASA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 1
- 229950000285 anacetrapib Drugs 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- GNVWVYIAQBJHGV-UHFFFAOYSA-N azetidin-3-ylmethanol Chemical group OCC1CNC1 GNVWVYIAQBJHGV-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 1
- 229950011033 cenicriviroc Drugs 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000009950 chronic meningitis Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VNWKTOKETHGBQD-MICDWDOJSA-N deuteriomethane Chemical compound [2H]C VNWKTOKETHGBQD-MICDWDOJSA-N 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950001279 elafibranor Drugs 0.000 description 1
- 229950000234 emricasan Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 108091008559 estrogen-related receptor alpha Proteins 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007603 infrared drying Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XIKIUQUXDNHBFR-UHFFFAOYSA-N monobenzyl phthalate Chemical compound OC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 XIKIUQUXDNHBFR-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 125000000627 niacin group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical group OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- MRWFZSLZNUJVQW-DEOSSOPVSA-N saroglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCN1C(C=2C=CC(SC)=CC=2)=CC=C1C MRWFZSLZNUJVQW-DEOSSOPVSA-N 0.000 description 1
- 229950006544 saroglitazar Drugs 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010023 transfer printing Methods 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229950003931 volixibat Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
本发明公开了一种五环三萜类新型AMPK激动剂齐墩果酸和δ‑齐墩果酸的衍生物及其医药用途,具体如式I或式II所示的化合物、其药学上可接受的盐或酯或溶剂化物,它们可用制备具有增强AMPK磷酸化水平活性的AMPK激动剂以及用于制备预防或治疗AMPK介导的疾病的药物。本发明的新型五环三萜类化合物具有显著的AMPK激动活性,且其活性显著优于公认的AMPK激动剂AICAR,同时具有更好的口服生物利用度等药代动力学性质和非常好的安全性;
Description
技术领域
本发明涉及生物医药领域,涉及具有AMPK激动活性的新型五环三萜类化合物,具体涉及齐墩果酸和δ-齐墩果酸的衍生物及其医药用途,本发明还涉及该类化合物在制备预防或治疗AMPK介导的疾病的药物中的用途及其药物组合物。
背景技术
AMPK(腺苷酸活化蛋白激酶)是调控机体能量代谢及炎症反应的关键激酶,其磷酸化激活可克服胰岛素抵抗、降血糖、降血脂(通过抑制脂肪酸及胆固醇的合成)、抗炎、抗凋亡、抗纤维化、促进线粒体合成、增强线粒体的氧化代谢、抗衰老和抗肿瘤等(Physiol.Rev.2009,89,1025)。近年来,AMPK的抗炎及抗纤维化作用已越发受到关注(Nature 2013,493,346),其可能的机制是AMPK通过增强***相关受体α(ERRα)的转录功能而发挥抗炎和抗纤维化作用(Immunity 2015,43,80)。
越来越多的证据表明,AMPK功能异常与多种疾病的发生发展密切相关。AMPK介导的疾病包括代谢性疾病和心脑血管疾病,如胰岛素抵抗、代谢综合征、1型或2型糖尿病、高脂血症、肥胖症、动脉粥样硬化、心肌缺血、心肌梗死、心律失常、冠心病、高血压、心衰、心肌肥大、心肌炎、糖尿病并发症(包括糖尿病心肌病、糖尿病肾病、视网膜病变、神经病变和糖尿病溃疡等)、非酒精性脂肪肝、非酒精性脂肪性肝炎、酒精性脂肪肝、肝硬化、痛风、中风或脑梗死等;AMPK介导的疾病还包括炎症疾病、自身免疫性疾病、器官纤维化疾病、神经损伤性疾病或病原体感染所致的继发性疾病,如肺炎、哮喘、慢性阻塞性肺病、慢性支气管炎、肺气肿、闭塞性细支气管炎、特发性肺纤维化、囊性纤维化肺病、过敏性鼻炎、炎性肠病(如克罗恩病和溃疡性结肠炎)、多囊肾病、***(PCOS)、***、***性红斑狼疮、类风湿关节炎、脊椎关节炎、骨关节炎、滑膜炎、肌腱炎、血栓闭塞性脉管炎、静脉炎、间歇性跛行、瘢痕瘤、银屑病、鱼鳞癣、大疱性类天疱疮、皮炎、接触性皮炎、胰腺炎、慢性肾炎、膀胱炎、脑膜炎、胃炎、败血症、坏疽性脓皮症、葡萄膜炎、帕金森病、阿尔茨海默病、α-共核蛋白病、抑郁症、多发性硬化症、肌萎缩侧索硬化病、纤维肌痛综合症、神经痛、唐氏综合征、哈勒沃登-施帕病、亨廷顿舞蹈病或威尔逊病等。
文献报道AMPK激动剂可预防和治疗多种AMPK介导的疾病(J.Med.Chem.,2015,582;Nature 2013,493,346;Experimental Neurology 2017,298,31;BiochemicalPharmacology 2010,80,1708;Current Drug Targets,2016,17,908;Nat Rev DrugDiscov,2019,DOI:10.1038/s41573-019-0019-2)。例如,临床上广泛使用的降糖药二甲双胍认为主要是通过激活AMPK而发挥多种临床功效(J.Clin.Invest.2001,108,1167)。尽管AMPK激动剂具有广泛的临床应用前景,然而,迄今为止,研制新型安全、有效的AMPK激动剂尚未取得实质性进展。由于安全性或有效性的原因,在研的AMPK激动剂进入临床研究阶段的寥寥无几。例如,广谱AMPK-β亚基激动剂MK-8722尽管可以降血糖,但在大鼠和猴子实验中发现动物心脏发生不可逆性心肌肥厚副作用(Science 2017,357,507)。此外,AICAR作为最常用的AMPK激动剂之一(Eur.J.Biochem.1995,229,558),也因其较大的毒副作用而被终止了临床实验(J Clin Pharmacol 1991,31:342–347)。
总之,临床上亟需开发活性高、毒副作用小的新型AMPK激动剂。另一方面,齐墩果酸是药用植物中常见的一个五环三萜,其具有广泛的生物活性(Nat Prod Rep 2011,28,543)。而3β-羟基-齐墩果烷-13(18)-烯-28-酸(δ-齐墩果酸)是一个在自然界中非常罕见的五环三萜酸(Phytochemistry 1999,51,83)。迄今,极少有文献报道δ-齐墩果酸的生物活性。
发明内容
发明目的:针对AMPK激动剂研发领域现有技术存在的问题,本发明提供一种新型齐墩果酸和δ-齐墩果酸的衍生物;本发明提供的新型齐墩果酸衍生物或者δ-齐墩果酸衍生物是一种新型的AMPK激动剂,因而可用于制备预防或治疗AMPK介导的疾病的药物。
本发明人在对δ-齐墩果酸和齐墩果酸进行结构改造时,意外地发现了一系列强效的新型AMPK激动剂,且其AMPK激动活性显著地优于公认的AMPK激动剂AICAR。
技术方案:为了实现上述目的,如本发明所述如下式I或式II所示的δ-齐墩果酸衍生物或齐墩果酸衍生物、其药学上可接受的盐或酯或溶剂化物:
其中,
R1是H、C1-C5烷基或取代基Y取代的C1-C5烷基,所述取代基Y是OH、C(O)OH、C(O)NH2、NH2、NHC(O)CH3、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
Ra是非取代的或取代基L取代的C1-C5烷基,所述取代基L是一个或两个独立地选自下列的取代基:OH、C(O)OH、NH2、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基或NHC(O)CH(CH3)NHC(O)CH(CH3)NH;
R2是取代基Z取代的C1-C5烷基,所述取代基Z是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
R3是H或C1-C3烷基;
R4是取代基W取代的C1-C5烷基,所述取代基W是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基、二乙醇胺基或乙酰基氨基;
R5是连接在环上任一碳上的H、OH、F、NH2、C1-C3烷基氨基、COOH、C1-C3烷基、C1-C3烷氧基、环烷基氧基或杂环烷基氧基;
Q是CH2、O、NR6、S、SO2、CHR7或化学键;
R6是H、C1-C3烷基、C1-C3烷基酰基、C1-C3烷基磺酰基或取代基P取代的C1-C3烷基,所述取代基P是OH、COOH、NH2或C1-C3烷基氨基;
R7是OH、NH2、COOH、C1-C3烷基氨基、C1-C3烷氧基、环烷基氧基或杂环烷基氧基;
n是0、1或2;
m是0、1或2。
在某些优选的实施方案中,所述的式I或式II化合物、其药学上可接受的盐或酯或溶剂化物,
R1是H、C1-C5烷基或取代基Y取代的C1-C5烷基,所述取代基Y是OH、C(O)OH、C(O)NH2、NH2、NHC(O)CH3、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
Ra是非取代的或取代基L取代的C1-C5烷基,所述取代基L是一个或两个独立地选自下列的取代基:OH、C(O)OH、NH2、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基或NHC(O)CH(CH3)NHC(O)CH(CH3)NH;
R2是取代基Z取代的C1-C5烷基,所述取代基Z是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;R3是H;
R4是取代基W取代的C1-C5烷基,所述取代基W是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基、二乙醇胺基或乙酰基氨基;
R5是连接在环上任一碳上的H、OH、F、NH2、C1-C3烷基氨基或COOH;
Q是CH2、O、NR6、S、SO2或CHR7;
R6是H、C1-C3烷基、C1-C3烷基酰基、C1-C3烷基磺酰基或取代基P取代的C1-C3烷基,所述取代基P是OH、COOH、NH2或C1-C3烷基氨基;
R7是OH、NH2、COOH或C1-C3烷基氨基;
n是0或1;
m是0或1。
更进一步地,在所述式II化合物中,当取代基Z是N,N-二甲基氨基或三甲基铵基时,R不是H;当取代基W是乙酰基氨基时,R不是H。
在某些更优选的实施方案中,所述化合物或其药学上可接受的盐或酯或溶剂化物选自如下化合物:
本发明的化合物也可作为药用盐使用。该盐可为下列酸中的至少一种的酸盐:半乳糖二酸、D-葡糖醛酸、甘油磷酸、马尿酸、羟乙磺酸、乳糖酸、马来酸、1,5-萘二磺酸、萘-2-磺酸、新戊酸、对苯二甲酸、硫氰酸、胆酸、正十二烷基硫酸、苯磺酸、柠檬酸、D-葡萄糖,乙醇酸、乳酸、苹果酸、丙二酸、扁桃酸、磷酸、丙酸、盐酸、硫酸、酒石酸、琥珀酸、甲酸、氢碘酸、氢溴酸、甲烷磺酸、烟酸、硝酸、乳清酸、草酸、苦味酸、L-焦谷氨酸、糖精酸、水杨酸、龙胆酸、对甲苯磺酸、戊酸、棕榈酸、葵二酸、硬脂酸、月桂酸、乙酸、己二酸、碳酸、苯磺酸、乙烷二磺酸、乙基琥珀酸、富马酸、3-羟基萘-2-甲酸、1-羟基萘-2-甲酸、油酸、十一碳烯酸、抗坏血酸、樟脑酸、樟脑磺酸、二氯乙酸、乙烷磺酸。另一方面,该盐也可以是本发明的化合物与金属(包括钠、钾、钙等)离子或药学上可接受的胺(包括乙二胺、氨丁三醇等)、铵离子或胆碱形成的盐。本发明的化合物也可以按酯、前药形式、N-氧化物或其溶剂化物组成药物组合物。
齐墩果酸可商业化购买。δ-齐墩果酸的合成可参照文献方法(Org.Biomol.Chem.,2016,14,11154)进行,即首先参照文献方法制得δ-齐墩果酸的苄酯,再经过常规的催化氢化脱苄反应即可制得δ-齐墩果酸。δ-齐墩果酸和齐墩果酸衍生物的合成可参照实施例的方法或改进的方法进行。
本发明提供了所述的式I或式II化合物、其药学上可接受的盐或酯或溶剂化物在制备具有增强AMPK磷酸化水平活性的AMPK激动剂中的应用。本发明的化合物对AMPK具有显著的激动活性,因而可用于制备具有增强AMPK磷酸化水平活性的AMPK激动剂。
本发明还提供了所述的式I或式II化合物、其药学上可接受的盐或酯或溶剂化物在制备预防或治疗AMPK介导的疾病的药物中的用途。
其中,所述AMPK介导的疾病包括代谢性疾病、心脑血管疾病、炎症疾病、自身免疫性疾病、器官纤维化疾病、神经退行性疾病、病原体感染所致的继发性疾病、线粒体功能障碍或紊乱疾病或肿瘤。
所述AMPK介导的疾病,如代谢性疾病和心脑血管疾病,包括:如胰岛素抵抗、代谢综合征、1型或2型糖尿病、高脂血症、肥胖症、动脉粥样硬化、心肌缺血、心肌梗死、心律失常、冠心病、高血压、心衰、心肌肥大、心肌炎、糖尿病并发症(包括糖尿病心肌病、糖尿病肾病、视网膜病变、神经病变和糖尿病溃疡等)、非酒精性脂肪肝、非酒精性脂肪性肝炎、酒精性脂肪肝、肝硬化、痛风、中风或脑梗死等。
所述AMPK介导的疾病,如炎症疾病、自身免疫性疾病、器官纤维化疾病、神经损伤性疾病或病原体感染所致的继发性疾病,包括:肺炎、哮喘、慢性阻塞性肺病、慢性支气管炎、肺气肿、闭塞性细支气管炎、特发性肺纤维化、囊性纤维化肺病、过敏性鼻炎、炎性肠病(如克罗恩病和溃疡性结肠炎)、多囊肾病、***(PCOS)、***、***性红斑狼疮、类风湿关节炎、脊椎关节炎、骨关节炎、滑膜炎、肌腱炎、血栓闭塞性脉管炎、静脉炎、间歇性跛行、瘢痕瘤、银屑病、鱼鳞癣、大疱性类天疱疮、皮炎、接触性皮炎、胰腺炎、慢性肾炎、膀胱炎、脑膜炎、胃炎、败血症、坏疽性脓皮症、葡萄膜炎、帕金森病、阿尔茨海默病、α-共核蛋白病、抑郁症、多发性硬化症、肌萎缩侧索硬化病、纤维肌痛综合症、神经痛、唐氏综合征、哈勒沃登-施帕病、亨廷顿舞蹈病或威尔逊病等。
所述AMPK介导的疾病,如线粒体功能障碍和紊乱疾病,包括:肌无力、肌阵挛、运动不耐受、卡恩斯-赛尔综合征、慢性疲乏综合征、利氏综合征、线粒体肌病-脑病-高乳酸血症、中风综合征或中风样发作。同样,本发明的化合物也可用于治疗肌肉营养不良状态,例如,杜氏肌营养不良、贝壳肌营养不良或弗立德希氏共济失调。
所述AMPK介导的疾病,如肿瘤,包括:骨癌、急性骨髓性白血病、慢性骨髓性白血病、急性淋巴细胞系白血病、慢性淋巴细胞系白血病、骨髓增生性疾病、多发性骨髓瘤、骨髓增生异常综合征、霍奇金氏淋巴瘤、非霍奇金氏淋巴瘤、血管瘤、肉芽瘤、黄瘤、脑膜肉瘤、神经胶质瘤、星形细胞瘤、成神经管细胞瘤、室管膜瘤、生殖细胞瘤(松果体瘤)、多形性成胶质细胞瘤、少突神经胶质细胞瘤、神经鞘瘤、成视网膜细胞瘤、纤维神经瘤、肉瘤、食道癌、胃癌、胰腺癌、大肠癌、结肠癌、直肠癌、肾癌、***癌、淋巴癌、睾丸癌、***癌、肺癌、肝癌、皮肤癌、恶性黑素瘤或基底细胞癌等。
本发明所述一种预防或治疗AMPK介导的疾病的药物组合物,其中含有治疗有效量的式I或式II化合物或其药学上可接受的盐或酯或溶剂化物作为活性成份和药学上可接受的辅料。可任意混合的辅料根据剂型、给药形式等可以改变。辅料的例子包括赋形剂、粘合剂、崩解剂、润滑剂、矫味剂、香味剂、着色剂或甜味剂等。所述药物组合物可以是胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、软膏剂、栓剂或贴剂等制剂学上常规的制剂形式。
如果需要,本发明的式I或式II化合物或其药学上可接受的盐或酯或溶剂化物可与一种或多种其他类型的预防或治疗AMPK介导的疾病的药物联合使用,包括但不限于以下几种联合用药的情形。
可选择与本发明的化合物联合使用的药物可以是一种或多种抗糖尿病药物,包括二甲双胍、磺酰脲类降糖药(如格列苯脲和格列美脲等)、葡萄糖苷酶抑制剂(如阿卡波糖和米格列醇等)、PPARγ激动剂(如吡格列酮和罗格列酮)、PPARα/γ双重激动剂、二肽基肽酶IV(DPP-IV)抑制剂(如西格列汀、沙格列汀、阿格列汀和利格列汀等)、格列奈类降糖药(如瑞格列奈和那格列奈等)、SGLT2抑制剂(如坎格列净、达格列净、恩格列净、依格列净、鲁格列净和托格列净等)、葡萄糖激酶激动剂(如HMS5552等)、胰岛素、胰高血糖素样肽-1(GLP-1)类药物(如埃塞那肽、利拉鲁肽、利司那肽、杜拉鲁肽、贝那鲁肽和阿必鲁肽等)、PTP1B抑制剂、糖原磷酸化酶抑制剂、葡萄糖-6-磷酸酶抑制剂、AMPK激动剂、GPR40激动剂或GPR120激动剂。
可选择与本发明的化合物联合使用的药物可以是一种或多种减肥药物,包括氯卡色林、奥利司他和胰高血糖素样肽-1(GLP-1)类药物(如埃塞那肽、利拉鲁肽、利司那肽、杜拉鲁肽、贝那鲁肽和阿必鲁肽等)等。
可选择与本发明的化合物联合使用的药物可以是一种或多种抗非酒精性脂肪性肝病药物,包括:AMPK激动剂(如二甲双胍)、法尼酯X受体(FXR)激动剂(如奥贝胆酸、GS-9674、EDP-305和LJN452等)、乙酰辅酶A羧化酶(ACC)抑制剂(如GS-0976等)、凋亡信号调节激酶-1(ASK1)抑制剂(如Selonsertib等)、PPAR激动剂(如Elafibranor、Saroglitazar、IVA337和MSDC-0602K等)、半胱天冬酶(caspase)抑制剂(如Emricasan等)、硬脂酰辅酶A去饱和酶1(SCD1)抑制剂(如Aramchol等)、长效胰高血糖素样肽-1(GLP-1)受体激动剂(如Semaglutide等)、顶端钠依赖性胆盐转运体(ASBT)抑制剂(如Volixibat等)、血管粘附蛋白1(VAP-1)抑制剂(如BI 1467335等)、CCR5R阻断剂(如Cenicriviroc等)和甲状腺激素受体β(THR-β)激动剂(如MGL-3196等)等。
可选择与本发明的化合物联合使用的药物可以是一种或多种降血脂药物,包括烟酸、他汀类药物(如洛伐他丁、辛伐他汀、普伐他汀、美伐他汀、氟伐他汀、阿托伐他汀、西立伐他汀、罗伐他汀和pitavastatin)、胆固醇吸收抑制剂(如依折麦布等)、贝特类药物(如氯贝特、苯扎贝特、非诺贝特等)、PCSK9抑制剂(如Evolocumab和Alirocumab等)、CETP抑制剂(如anacetrapib等)、AMPK激动剂和ACC抑制剂(如GS-0976等)等。
本发明的式I或式II化合物或其药学上可接受的盐或酯或溶剂化物的用量可根据患者年龄、体重、症状和给药途径等而适当改变。当对成人(约60kg)给药时,式I或式II化合物或其药学上可接受的盐或酯或溶剂化物的给药剂量是1mg~1000mg/次,优选5mg~500mg/次,更优选10mg~60mg/次,每天给药1~3次。也可根据疾病程度的不同和剂型的不同而偏离此剂量范围。
有益效果:与现有技术相比,本发明具有如下优点:
(1)本发明的新型齐墩果酸和δ-齐墩果酸的衍生物具有强效的AMPK激动活性,且其活性显著优于公认的AMPK激动剂AICAR。
(2)与先导化合物δ-齐墩果酸和齐墩果酸相比,本发明的新型五环三萜类化合物具有更好的口服生物利用度等药代动力学性质。
(3)与现有的AMPK激动剂AICAR(因毒副作用大而终止了临床试验)和MK-8722(可导致不可逆性心肌肥厚副作用)相比,本发明的新型五环三萜类化合物具有非常好的安全性。
(4)本发明的新型五环三萜类化合物作为AMPK激动剂,比现有的AMPK激动剂具有成本低廉、易于制备及潜在的副作用小等优点,其即可单独使用,也可与一种或多种其他类型的预防或治疗AMPK介导的疾病的药物联合使用,有望成为新型预防或治疗AMPK介导的疾病的药物。
附图说明
图1为部分化合物对Huh-7细胞AMPK下游信号通路的影响图(Western Blot检测)。
具体实施方式
下面通过实施例具体说明本发明的内容。在本发明中,以下所述的实施例是为了更好的阐述本发明,并不是用来限制本发明的范围。在不背离本发明的精神和范围的前提下,可以对本发明进行各种变化和修饰。
实施例1
(2-(三甲基铵基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-1)
取化合物I-1(1.27g,5.0mmol)置于史莱克管中,加入三甲胺的四氢呋喃溶液(20mL,40mmol),氩气氛围下,55℃加热反应24小时。反应完毕后,用二氯甲烷将反应管中的混合物移至茄形瓶中,减压浓缩,残渣抽滤,滤饼用二氯甲烷(5mL×3)洗涤,得化合物I-2(白色固体,1.166g,产率75%)。
取化合物I-2(1.166g,3.723mmol)悬浮于三氯甲烷和乙醇(20mL,v:v=7:3)的混合溶液中,冷却至0℃后加入水合肼(340μL),氩气氛围下,50℃加热回流反应12小时。反应完毕后,反应液抽滤,滤饼用三氯甲烷和乙醇(5mL×3,v:v=8.5:1.5)的混合溶剂洗涤,滤液浓缩,干燥,得到化合物I-3的粗品直接用于下一步反应。
将上步得到化合物I-3的粗品溶于去离子水(2mL)中,冷却至0℃,加入氢溴酸水溶液(2mL,48%),0℃下搅拌1小时。反应液中加入甲苯和甲醇(5mL,v:v=4.5:0.5)的混合溶剂,与45℃下减压浓缩,此操作重复两次后大量白色固体析出,抽滤,滤饼用去离子水(1mL×2)洗涤。滤液继续加入甲苯和甲醇(5mL,v:v=4.5:0.5)的混合溶剂,与45℃下减压浓缩直至除去绝大部分溶剂,加入乙腈(5mL)打浆,抽滤,滤饼用少量甲醇(1mL)洗涤,干燥,得化合物I-4(白色固体,915mg,两步产率93%):1H NMR(300MHz,D2O)δ3.82–3.73(m,2H),3.66–3.57(m,2H),3.30(s,9H).
取δ-齐墩果酸(δ-OA,100mg,0.219mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(122μL,0.876mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,108mg,0.284mmol),反应1小时后加入化合物I-4(58mg,0.219mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和去离子水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,去离子水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=10:1)纯化,得化合物I-5(白色固体,41mg,产率30%)。
取化合物I-5(175mg,0.281mmol)悬浮于无水二氯甲烷(10mL)中,依次加入N,N'-二环己基碳酰亚胺(DCC,232mg,1.124mmol)、4-二甲氨基吡啶(DMAP,34mg,0.281mmol)和邻苯二甲酸单苄酯(86mg,0.337mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用去离子水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物I-6(白色固体,100mg,产率41%)。
取化合物I-6(100mg,0.116mmol)溶于四氢呋喃(8mL)中,加入10%钯碳(10mg),氢气氛围下室温搅拌反应过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=10:1)纯化,得化合物A-1(白色固体,66mg,产率73%):1H NMR(300MHz,DMSO-d6)δ13.18(s,1H),7.79–7.69(m,1H),7.69–7.57(m,3H),7.17–7.08(m,1H),4.74–4.60(m,1H),3.59–3.43(m,2H),3.12(s,9H),2.81(d,J=14.1Hz,1H),2.49–2.37(m,1H),2.17(d,J=13.2Hz,1H),1.18(s,3H),0.93(s,3H),0.91(s,9H),0.84(s,3H),0.74(s,3H).ESI-MS:m/z 689.6[M-Br]+。
实施例2
N-(2-(二甲基氨基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-3)
取δ-齐墩果酸(5g,0.011mol)溶于无水吡啶(35mL)中,搅拌下缓慢滴加醋酸酐(4mL),滴加完毕后加热回流反应1小时。TLC检测反应完全后,反应液冷却至室温,将其滴入冰水(20mL×2)中,析出大量白色固体,抽滤,滤饼用水洗(10mL×3),正己烷洗(10mL×3),真空干燥,乙醇重结晶,得化合物II-1(白色固体,4.52g,产率83%)。
取化合物II-1(150mg,0.30mmol)溶于无水二氯甲烷(5mL)中,搅拌下缓慢滴加草酰氯(130μL,1.50mmol)和N,N-二甲基甲酰胺(1滴),室温反应3小时。TLC检测反应完全后,减压蒸除溶剂,得化合物II-2(黄色固体,155mg,产率100%)。
将N,N-二甲基乙二胺(66μL,0.60mmol)溶于无水二氯甲烷(5mL)中,搅拌下缓慢滴加化合物II-2(155mg,0.30mmol)的无水二氯甲烷(5mL)溶液和三乙胺(84 μL,0.60mmol),室温反应5小时。TLC检测反应完全后,加入二氯甲烷(10mL)稀释反应液,反应液依次用饱和碳酸氢钠溶液(10mL×3)、水(10mL×3)和饱和食盐水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物II-3(白色固体,143mg,产率84%)。
将化合物II-3(141mg,0.248mmol)悬浮于甲醇(10mL)中,加入氢氧化钾(140mg,2.48mmol),室温搅拌过夜。TLC检测反应完全后,反应液冷却至室温,减压蒸除溶剂,残余物用乙酸乙酯(20mL)和水(20mL)处理,有机相依次用水(20mL×3)和饱和食盐水(20mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物II-4(白色固体,87mg,产率67%)。
将化合物II-4(87mg,0.165mmol)溶于无水吡啶(10mL)中,加入邻苯二甲酸酐(245mg,1.65mmol)和4-二甲氨基吡啶(20mg,0.165mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(20mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-3(白色固体,93mg,产率84%):1H NMR(300MHz,CDCl3)δ7.84–7.63(m,1H),7.63–7.51(m,1H),7.51–7.30(m,2H),6.72–6.50(m,1H),4.82–4.59(m,1H),3.77–3.43(m,2H),3.07–2.83(m,2H),2.83–2.70(m,1H),2.63(s,6H),2.41(d,J=13.7Hz,1H),2.36–2.18(m,1H),1.16(s,3H),0.98(s,3H),0.87(s,9H),0.83(s,3H),0.72(s,3H).ESI-MS:m/z 673.3[M-H]-。
实施例3
N-(2-(1-哌啶基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-4)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1-(2-氨基乙基)哌啶,制得化合物A-4:1H NMR(300MHz,CDCl3)δ7.74(d,J=7.1Hz,1H),7.52(d,J=6.9Hz,1H),7.47–7.29(m,2H),6.77–6.64(m,1H),4.78–4.59(m,1H),3.75–3.46(m,2H),3.08–2.67(m,7H),2.43(d,J=13.6Hz,1H),2.31(d,J=10.1Hz,1H),1.16(s,3H),0.98(s,3H),0.88(s,3H),0.86(s,6H),0.79(s,3H),0.72(s,3H).ESI-MS:m/z 715.5[M+H]+。
实施例4
N-(2-(4-吗啉基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-5)
参照实施例2的方法,将N,N-二甲基乙二胺替换成4-(2-氨基乙基)吗啉,制得化合物A-5:1H NMR(500MHz,CDCl3)δ7.76(d,J=5.8Hz,1H),7.63(d,J=5.8Hz,1H),7.52–7.41(m,2H),6.57–6.46(m,1H),4.76–4.67(m,1H),3.76(s,4H),3.57–3.38(m,2H),2.81(d,J=13.8Hz,1H),2.63(s,6H),2.45(d,J=13.5Hz,1H),2.42–2.33(m,1H),1.18(s,3H),0.95(s,3H),0.90(s,3H),0.89(s,3H),0.87(s,3H),0.84(s,3H),0.74(s,3H).ESI-MS:m/z 715.5[M-H]-。
实施例5
N-(2-(1-四氢吡咯基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-6)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1-(2-氨基乙基)吡咯烷,制得化合物A-6:1H NMR(300MHz,CDCl3)δ7.73(d,J=7.3Hz,1H),7.49(d,J=7.1Hz,1H),7.37(dt,J=19.0,7.3Hz,2H),4.78–4.65(m,1H),3.72–3.54(m,2H),3.26–3.08(m,4H),3.08–2.95(m,2H),2.77(d,J=13.3Hz,1H),2.42(d,J=13.5Hz,1H),2.31(d,J=12.0Hz,1H),1.16(s,3H),1.02(s,3H),0.88(s,3H),0.86(s,6H),0.82(s,3H),0.72(s,3H).ESI-MS:m/z 699.3[M-H]-。
实施例6
N-(2-(4-甲基-1-哌嗪基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-8)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1-(2-氨基乙基)-4-甲基哌嗪,制得化合物A-8:1H NMR(300MHz,CDCl3)δ7.75(d,J=6.9Hz,1H),7.64(d,J=7.0Hz,1H),7.53–7.35(m,2H),6.46–6.36(m,1H),4.80–4.69(m,1H),3.54–3.30(m,2H),3.04–2.80(m,4H),2.73(s,5H),2.57(s,5H),2.53–2.45(m,1H),2.46–2.38(m,1H),1.24(s,3H),1.00(s,3H),0.97(s,3H),0.93(s,9H),0.78(s,3H).ESI-MS:m/z 730.5[M+H]+。
实施例7
N-(2-(4-吗啉基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-12)
取齐墩果酸(OA,20g,0.044mol)溶于N,N-二甲基甲酰胺(200mL)中,加入碳酸钾(6g,0.044mol),搅拌下缓慢滴加溴化苄(8mL,0.044mol),滴加完毕后将反应液升温至85℃,反应10小时。TLC检测反应完全后,趁热抽滤,滤饼用热的N,N-二甲基甲酰胺(10mL×3)洗涤,滤液冷却至室温后滴入冰水(100mL×2)中,析出大量白色固体,抽滤,滤饼用水洗(50mL×3),正己烷洗(50mL×3),真空干燥,得化合物III-1(白色固体,22.02g,产率92%)。
取化合物III-1(22g,0.040mol)溶于二氯甲烷(200mL)中,加入质子化蒙脱土(44g),将反应液升温至40℃,反应8小时。TLC检测反应完全后,冷却至室温,抽滤,滤饼用二氯甲烷(50mL×3)洗涤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=10:1)纯化,得化合物III-2(白色固体,16.52g,产率75%)。
将化合物III-2(1g,1.829mmol)溶于无水吡啶(10mL)中,加入邻苯二甲酸酐(2.708g,18.29mmol)和4-二甲氨基吡啶(223mg,1.829mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(30mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物III-3(白色固体,925mg,产率73%)。
取化合物III-3(150mg,0.216mmol)溶于无水二氯甲烷(6mL)中,依次加入N,N'-二环己基碳酰亚胺(134mg,0.647mmol)、4-二甲氨基吡啶(27mg,0.216mmol)和N-乙酰乙醇胺(30μL,0.324mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=3:1)纯化,得化合物III-4(白色固体,159mg,产率95%)。
取化合物III-4(159mg,0.204mmol)溶于四氢呋喃(10mL)中,加入10%钯碳(16mg),氢气氛围下室温搅拌反应过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=1:1)纯化,得化合物III-5(白色固体,90mg,产率64%)
取化合物III-5(100mg,0.145mmol)溶于N,N-二甲基甲酰胺(6mL)中,加入三乙胺(40μL,0.290mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(72mg,0.188mmol),反应1小时后加入N-(2-氨基乙基)吗啉(23μL,0.174mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物A-12(白色固体,80mg,产率69%):1H NMR(300MHz,CDCl3)δ7.81(d,J=7.3Hz,1H),7.66(d,J=7.0Hz,1H),7.63–7.50(m,2H),6.60–6.49(m,1H),6.49–6.36(m,1H),4.77–4.65(m,1H),4.44(t,J=4.8Hz,2H),3.76–3.56(m,6H),3.47–3.25(m,2H),2.86(d,J=15.4Hz,1H),2.53–2.33(m,8H),2.03(s,3H),1.21(s,3H),0.97(s,3H),0.96(s,6H),0.94(s,3H),0.89(s,3H),0.75(s,3H).ESI-MS:m/z 824.6[M+Na]+。
实施例8
N-(2-(4-甲基-1-哌嗪基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-14)
参照实施例7的方法,将4-(2-氨基乙基)吗啉替换成1-(2-氨基乙基)-4-甲基哌嗪,制得化合物A-14:1H NMR(300MHz,CDCl3)δ7.81(d,J=7.2Hz,1H),7.66(d,J=7.0Hz,1H),7.62–7.48(m,2H),6.58–6.48(m,1H),6.45–6.36(m,1H),4.76–4.67(m,1H),4.44(t,J=4.8Hz,2H),3.73–3.55(m,2H),3.43–3.21(m,2H),2.85(d,J=15.3Hz,1H),2.71–2.51(m,6H),2.51–2.42(m,4H),2.42–2.38(m,1H),2.36(s,4H),2.03(s,3H),1.20(s,3H),0.97(s,3H),0.95(s,9H),0.90(s,3H),0.75(s,3H).ESI-MS:m/z 815.7[M+H]+。
实施例9
N-(2-(三甲基铵基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-15)
参照实施例7的方法制得化合物III-5,取化合物III-5(100mg,0.145mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(80μL,0.580mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(72mg,0.188mmol),反应1小时后加入化合物I-4(60mg,0.174mmol)(由实施例1制得),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和去离子水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,去离子水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物A-15(白色固体,80mg,产率65%):1H NMR(300MHz,DMSO-d6)δ8.09–7.98(m,1H),7.83–7.74(m,2H),7.74–7.64(m,2H),7.17–7.06(m,1H),4.74–4.61(m,1H),4.30–4.14(m,2H),3.59–3.45(m,2H),3.44–3.33(m,4H),3.13(s,9H),2.91–2.72(m,1H),2.48–2.39(m,1H),2.18(d,J=12.1Hz,1H),1.84(s,3H),1.19(s,3H),0.92(s,12H),0.86(s,3H),0.75(s,3H).ESI-MS:m/z 774.6[M-Br]+。
实施例10
N-(3-(三甲基铵基)丙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-16)
参照实施例1的方法,将化合物I-1替换成I-1’,制得化合物I-4’。再参照实施例9的方法,将化合物I-4替换成I-4’,制得化合物A-16:1H NMR(300MHz,DMSO-d6)δ8.08–7.96(m,1H),7.79–7.71(m,2H),7.67(d,J=8.6Hz,2H),7.04–6.88(m,1H),4.71–4.60(m,1H),4.29–4.13(m,2H),3.41–3.29(m,2H),3.29–3.18(m,2H),3.18–3.08(m,2H),3.04(s,9H),2.79(d,J=12.5Hz,1H),2.43(d,J=14.3Hz,1H),2.17(d,J=12.9Hz,1H),1.81(s,3H),1.16(s,3H),0.90(s,12H),0.83(s,3H),0.72(s,3H).ESI-MS:m/z 788.6[M-Br]+。
实施例11
N-(2-(三甲基铵基)乙基)-3β-(2-甲氧酰基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-17)
参照实施例7的方法制得化合物III-2,取化合物III-2(150mg,0.274mmol)溶于无水二氯甲烷(6mL)中,依次加入N,N'-二环己基碳酰亚胺(170mg,0.823mmol)、4-二甲氨基吡啶(34mg,0.274mmol)和邻苯二甲酸单甲酯(54mg,0.302mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=20:1)纯化,得化合物IV-1(白色固体,159mg,产率82%)。
取化合物IV-1(159mg,0.224mmol)溶于四氢呋喃(10mL)中,加入10%钯碳(20mg),氢气氛围下室温搅拌过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=1:1)纯化,得化合物IV-2(白色固体,118mg,产率85%)。
取化合物IV-2(150mg,0.242mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(135μL,0.970mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(120mg,0.315mmol),反应1小时后加入化合物I-4(128mg,0.485mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和去离子水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,去离子水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-17(白色固体,77mg,产率40%):1HNMR(300MHz,DMSO-d6)δ7.82–7.64(m,4H),7.18–7.06(m,1H),4.74–4.64(m,1H),3.83(s,3H),3.59–3.45(m,2H),3.39–3.34(m,2H),3.13(s,9H),2.83(d,J=13.4Hz,1H),2.50–2.41(m,1H),2.24–2.11(m,1H),1.19(s,3H),0.93(s,6H),0.92(s,6H),0.86(s,3H),0.75(s,3H).ESI-MS:m/z 703.6[M-Br]+。
实施例12
N-(3-(三甲基铵基)丙基)-3β-(2-甲氧酰基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-18)
参照实施例11的方法,将化合物I-4替换成I-4’,制得化合物A-18:1H NMR(300MHz,DMSO-d6)δ7.80–7.63(m,4H),7.02–6.89(m,1H),4.76–4.62(m,1H),3.82(s,3H),3.30–3.20(m,2H),3.20–3.10(m,2H),3.06(s,9H),2.81(d,J=14.7Hz,1H),2.46(d,J=14.8Hz,1H),2.20(d,J=13.1Hz,1H),1.19(s,3H),0.93(s,12H),0.86(s,3H),0.74(s,3H).ESI-MS:m/z 717.7[M-Br]+。
实施例13
N-(3-(二甲基氨基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-19)
取δ-齐墩果酸(δ-OA,100mg,0.219mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(122μL,0.876mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(108mg,0.285mmol),反应1小时后加入3-二甲胺基丙胺(55μL,0.438mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物V-1(白色固体,113mg,产率96%)。
将化合物V-1(113mg,0.209mmol)溶于无水吡啶(8mL)中,加入邻苯二甲酸酐(309mg,2.09mmol)和4-二甲氨基吡啶(26mg,0.209mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(20mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-19(白色固体,121mg,产率84%):1H NMR(300MHz,CDCl3)δ7.72(d,J=7.2Hz,1H),7.55(d,J=7.1Hz,1H),7.47–7.30(m,2H),6.36–6.27(m,1H),4.76–4.65(m,1H),3.46–3.18(m,2H),2.91–2.72(m,3H),2.62(s,6H),2.43(d,J=14.2Hz,1H),2.39–2.30(m,1H),1.17(s,3H),0.98(s,3H),0.89(s,3H),0.87(s,6H),0.82(s,3H),0.72(s,3H).ESI-MS:m/z 689.6[M+H]+。
实施例14
N-(3-(4-吗啉基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-20)
参照实施例13的方法,将3-二甲胺基丙胺替换成N-(3-氨丙基)吗啉,制得化合物A-20:1H NMR(300MHz,CDCl3)δ7.90–7.78(m,1H),7.72–7.59(m,1H),7.59–7.46(m,2H),6.40–6.25(m,1H),4.79–4.66(m,1H),4.13–3.93(m,4H),3.50–3.22(m,2H),3.21–3.04(m,2H),3.04–2.88(m,2H),2.81(d,J=13.7Hz,1H),2.47(d,J=13.8Hz,1H),2.35(d,J=11.9Hz,1H),2.17–2.00(m,2H),1.19(s,3H),0.95(s,3H),0.89(s,6H),0.87(s,6H),0.73(s,3H).
实施例15
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰基)-吗啉(化合物A-27)
参照实施例2的方法,将N,N-二甲基乙二胺替换成吗啉,制得化合物A-27:1H NMR(300MHz,DMSO)δ7.94–7.85(m,1H),7.78–7.68(m,1H),7.63–7.49(m,2H),4.84–4.74(m,1H),3.80(s,4H),3.63(s,4H),2.77(d,J=14.5Hz,1H),2.46(d,J=13.2Hz,2H),1.19(s,3H),0.97(s,3H),0.92(s,3H),0.91(s,3H),0.90(s,3H),0.87(s,3H),0.79(s,3H).ESI-MS:m/z 672.5[M-H]-。
实施例16
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(4-吗啉基)乙酯(化合物A-44)
参照实施例7的方法制得化合物III-5,取化合物III-5(120mg,0.174mmol)溶于N,N-二甲基甲酰胺(10mL)中,加入4-(2-溴乙基)吗啉氢溴酸盐(57mg,0.208mmol)和碳酸钾(70mg,0.522mmol),室温搅拌反应。TLC检测反应完全后,用乙酸乙酯(20mL)和(10mL)处理反应液,水层用乙酸乙酯(10mL)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-44(白色固体,87mg,产率62%):1H NMR(300MHz,CDCl3)δ7.86–7.78(m,1H),7.69–7.63(m,1H),7.63–7.49(m,2H),6.64–6.47(m,1H),4.77–4.67(m,1H),4.44(t,J=4.8Hz,2H),4.30–4.13(m,2H),3.77–3.55(m,6H),2.75(d,J=14.0Hz,1H),2.59(t,J=5.7Hz,2H),2.54–2.46(m,4H),2.42(d,J=14.1Hz,1H),2.18(d,J=6.9Hz,1H),2.03(s,3H),1.17(s,3H),0.96(s,6H),0.94(s,3H),0.93(s,3H),0.92(s,3H),0.74(s,3H).ESI-MS:m/z 825.6[M+Na]+。
实施例17
N-(2-(三甲基铵基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-66)
参照实施例1的方法制得化合物A-66:1H NMR(300MHz,DMSO-d6)δ7.16–7.03(m,1H),4.31(d,J=5.1Hz,1H),3.59–3.41(m,2H),3.08–2.92(m,2H),2.80(d,J=12.4Hz,1H),2.45(d,J=14.4Hz,1H),2.17(d,J=13.4Hz,1H),1.15(s,3H),0.91(s,3H),0.90(s,6H),0.85(s,3H),0.73(s,3H),0.68(s,3H).ESI-MS:m/z541.5[M-Br]+。
实施例18
N-(3-(三甲基铵基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺溴化物(化合物A-67)
参照实施例1的方法,将化合物I-4替换成I-4’,制得化合物A-67:1H NMR(300MHz,DMSO-d6)δ7.00–6.89(m,1H),4.31(d,J=5.0Hz,1H),3.28–3.19(m,2H),3.19–3.09(m,2H),3.05(s,9H),2.79(d,J=13.4Hz,1H),2.44(d,J=13.9Hz,1H),2.18(d,J=13.3Hz,1H),1.15(s,3H),0.90(s,9H),0.85(s,3H),0.72(s,3H),0.68(s,3H).ESI-MS:m/z 555.5[M-Br]+。
实施例19
N-(2-(二甲基氨基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-68)
参照实施例2的方法制得化合物A-68:1H NMR(300MHz,CDCl3)δ6.45(t,J=4.7Hz,1H),3.45–3.31(m,2H),3.30–3.21(m,1H),2.93–2.80(m,1H),2.54–2.31(m,4H),2.23(s,6H),1.22(s,3H),1.03(s,3H),0.97(s,3H),0.94(s,3H),0.93(s,3H),0.81(s,3H),0.78(s,3H).ESI-MS:m/z 527.5[M+H]+。
实施例20
N-(2-(1-哌啶基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-69)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1-(2-氨基乙基)哌啶,制得化合物A-69:1H NMR(300MHz,CDCl3)δ6.71–6.26(m,1H),3.47–3.32(m,1H),3.32–3.16(m,2H),2.93–2.78(m,1H),2.55–2.22(m,8H),1.18(s,3H),0.99(s,3H),0.94(s,3H),0.90(s,3H),0.88(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 567.5[M+H]+。
实施例21
N-(2-(4-吗啉烷基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-70)
参照实施例2的方法,将N,N-二甲基乙二胺替换成4-(2-氨基乙基)吗啉,制得化合物A-70:1H NMR(300MHz,CDCl3)δ6.50–6.40(m,1H),3.76–3.60(m,4H),3.45–3.29(m,2H),3.29–3.18(m,1H),2.90–2.79(m,1H),2.55–2.31(m,8H),1.19(s,3H),0.99(s,3H),0.94(s,3H),0.89(s,3H),0.87(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 569.5[M+H]+。
实施例22
N-(2-(4-甲基-1-哌嗪基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-73)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1-(2-氨基乙基)-4-甲基哌嗪,制得化合物A-73:1H NMR(300MHz,CDCl3)δ6.53–6.44(m,1H),3.47–3.33(m,1H),3.34–3.18(m,2H),2.90–2.80(m,1H),2.64–2.33(m,12H),2.28(s,3H),1.19(s,3H),0.99(s,3H),0.94(s,3H),0.90(s,3H),0.89(s,3H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z 582.5[M+H]+。
实施例23
N-(3-(二甲基氨基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-77)
参照实施例2的方法,将N,N-二甲基乙二胺替换成3-二甲氨基丙胺,制得化合物A-77:1H NMR(300MHz,CDCl3)δ6.24(t,J=5.1Hz,1H),3.46–3.32(m,1H),3.29–3.11(m,2H),2.87–2.73(m,1H),2.50–2.42(m,1H),2.41–2.35(m,1H),2.31(t,J=7.1Hz,2H),2.22(s,6H),1.18(s,3H),0.99(s,3H),0.92(s,3H),0.91(s,3H),0.88(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 541.5[M+H]+。
实施例24
N-(3-(4-吗啉烷基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-78)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N-(3-氨丙基)吗啉,制得化合物A-78:1H NMR(300MHz,CDCl3)δ6.03(t,J=5.7Hz,1H),3.71(d,J=4.6Hz,4H),3.43–3.28(m,1H),3.28–3.14(m,2H),2.87–2.76(m,1H),2.53–2.30(m,8H),1.19(s,3H),0.99(s,3H),0.91(s,3H),0.90(s,3H),0.88(s,3H),0.78(s,3H),0.74(s,3H).ESI-MS:m/z 583.5[M+H]+。
实施例25
N-(2-(乙酰氨基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-83)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N-乙酰基乙二胺,制得化合物A-83:1H NMR(300MHz,CDCl3)δ6.49–6.35(m,1H),6.34–6.17(m,1H),3.55–3.28(m,4H),3.27–3.14(m,1H),2.88–2.74(m,1H),2.55–2.42(m,1H),2.42–2.30(m,1H),1.96(s,3H),1.19(s,3H),0.99(s,3H),0.91(s,6H),0.88(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 539.4[M-H]-。
实施例26
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-吗啉(化合物A-84)
参照实施例2的方法,将N,N-二甲基乙二胺替换成吗啉,制得化合物A-84:1H NMR(300MHz,CDCl3)δ4.01–3.69(m,4H),3.68–3.52(m,4H),3.27–3.17(m,1H),2.81–2.70(m,1H),2.54–2.38(m,2H),1.17(s,3H),0.99(s,3H),0.92(s,3H),0.87(s,3H),0.86(s,3H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z 548.4[M+Na]+。
实施例27
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物A-85)
参照实施例2的方法,将N,N-二甲基乙二胺替换成吗啉硫代吗啉-1,1-二氧化物,制得化合物A-85:1H NMR(300MHz,CDCl3)δ4.38–4.12(m,4H),3.28–3.17(m,1H),3.07–2.93(m,4H),2.81–2.70(m,1H),2.53–2.44(m,1H),2.44–2.33(m,1H),1.19(s,3H),0.99(s,3H),0.92(s,3H),0.87(s,3H),0.86(s,3H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z 572.4[M-H]-。
实施例28
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-4-甲基哌嗪(化合物A-87)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N-甲基哌嗪,制得化合物A-87:1H NMR(300MHz,CDCl3)δ4.01–3.58(m,4H),3.28–3.19(m,1H),2.83–2.71(m,1H),2.54–2.40(m,2H),2.40–2.31(m,4H),2.29(s,3H),1.17(s,3H),0.99(s,3H),0.91(s,3H),0.89(s,3H),0.88(s,3H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z 539.5[M+H]+。
实施例29
N-(2-(二甲基氨基)乙基)-N-甲基-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-102)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N,N,N'-三甲基乙二胺,制得化合物A-102:1H NMR(300MHz,CDCl3)δ3.66–3.53(m,1H),3.53–3.38(m,1H),3.32–3.24(m,1H),3.22(s,3H),2.83–2.71(m,1H),2.57–2.36(m,4H),2.32(s,6H),1.19(s,3H),1.01(s,3H),0.96(s,3H),0.93(s,3H),0.89(s,3H),0.81(s,3H),0.79(s,3H).ESI-MS:m/z 541.5[M+H]+。
实施例30
N-(2-(二乙基氨基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-103)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N,N-二乙基乙二胺,制得化合物A-103:1H NMR(300MHz,CDCl3)δ6.54–6.29(m,1H),3.50–3.32(m,1H),3.31–3.06(m,2H),2.87–2.78(m,1H),2.60–2.32(m,8H),1.18(s,3H),0.99(s,3H),0.93(s,3H),0.90(s,3H),0.88(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 555.4[M+H]+。
实施例31
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-哌啶(化合物A-104)
参照实施例2的方法,将N,N-二甲基乙二胺替换成哌啶,制得化合物A-104:1H NMR(300MHz,CDCl3)δ3.88–3.54(m,4H),3.31–3.22(m,1H),2.84–2.74(m,1H),2.54–2.37(m,2H),1.20(s,3H),1.02(s,3H),0.93(s,6H),0.91(s,3H),0.80(s,3H),0.80(s,3H).ESI-MS:m/z 546.4[M+Na]+。
实施例32
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-哌嗪(化合物A-86)
参照实施例2的方法,将N,N-二甲基乙二胺替换成哌嗪,制得化合物A-86:1H NMR(300MHz,CDCl3)δ3.87–3.64(m,3H),3.28–3.18(m,1H),2.88–2.78(m,3H),2.78–2.70(m,1H),2.45(d,J=12.8Hz,2H),2.00–1.87(m,2H),1.17(s,3H),0.99(s,3H),0.91(s,3H),0.88(s,6H),0.77(s,6H).ESI-MS:m/z 525.6[M+H]+。
实施例33
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-四氢吡咯(化合物A-88)
参照实施例2的方法,将N,N-二甲基乙二胺替换成四氢吡咯,制得化合物A-88:1HNMR(300MHz,CDCl3)δ3.66–3.49(m,4H),3.21(dd,J=10.6,5.6Hz,1H),2.84–2.69(m,1H),2.48–2.38(m,1H),2.38–2.30(m,1H),1.16(s,3H),0.98(s,3H),0.94(s,3H),0.89(s,3H),0.87(s,3H),0.77(s,3H),0.76(s,3H).ESI-MS:m/z 532.5[M+Na]+。
实施例34
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-(3S)-羟基-四氢吡咯(化合物A-91)
参照实施例2的方法,将N,N-二甲基乙二胺替换成(S)-3-吡咯烷醇,制得化合物A-91:1H NMR(300MHz,CDCl3)δ5.29(s,1H),4.49–4.36(m,1H),3.91–3.72(m,1H),3.73–3.54(m,3H),3.22(dd,J=9.6,4.9Hz,1H),2.76(d,J=14.9Hz,1H),2.50–2.39(m,1H),2.39–2.29(m,1H),2.22–2.09(m,1H),1.16(s,3H),0.98(s,3H),0.94(s,3H),0.90(s,3H),0.87(s,3H),0.77(s,3H),0.76(s,3H).ESI-MS:m/z 526.4[M+H]+。
实施例35
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-(3R)-羟基-四氢吡咯(化合物A-92)
参照实施例2的方法,将N,N-二甲基乙二胺替换成(R)-3-吡咯烷醇,制得化合物A-92:1H NMR(300MHz,CDCl3)δ4.50–4.34(m,1H),3.80–3.66(m,2H),3.68–3.60(m,2H),3.30–3.12(m,1H),2.75(d,J=14.8Hz,1H),2.48–2.37(m,1H),2.38–2.26(m,2H),1.15(s,3H),0.97(s,3H),0.95(s,3H),0.89(s,3H),0.86(s,3H),0.77(s,3H),0.75(s,3H).ESI-MS:m/z526.4[M+H]+。
实施例36
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-(2R)-羧基-四氢吡咯(化合物A-93)
参照实施例2的方法,将N,N-二甲基乙二胺替换成D-脯氨酸苄酯盐酸盐,制得化合物VI-1。
取化合物VI-1(120mg,0.186mmol)溶于四氢呋喃(1mL)和甲醇(1mL)的混合溶液中,加入2N氢氧化钠溶液(1mL),80℃下反应2小时。TLC检测反应完全后,减压蒸除溶剂,用1N盐酸溶液调节pH至弱酸性,二氯甲烷萃取(5mL×2),水洗(5mL×2)有机相,饱和食盐水洗涤(5mL×2),无水硫酸钠干燥,减压蒸除溶剂,残余物用二氯甲烷和乙腈的混合溶剂(5.5mL,v:v=10:1)于超声中处理,析出白色固体,抽滤,滤饼用二氯甲烷和乙腈的混合溶剂(5.5mL,v:v=10:1)洗涤两次,红外下干燥,得化合物A-93(白色固体,88mg,产率85%):1H NMR(300MHz,CDCl3)δ4.70(q,J=3.8Hz,1H),3.94–3.79(m,1H),3.72–3.59(m,1H),3.25(dd,J=10.8,5.4Hz,1H),2.79(dd,J=15.5,4.0Hz,1H),2.53–2.40(m,1H),2.38–2.21(m,2H),1.19(s,3H),1.01(s,3H),0.94(s,6H),0.89(s,3H),0.81(s,3H),0.78(s,3H).ESI-MS:m/z 552.4[M-H]-。
实施例37
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-(2S)-羧基-四氢吡咯(化合物A-94)
参照实施例36的方法,将D-脯氨酸苄酯盐酸盐替换成L-脯氨酸苄酯盐酸盐,制得化合物A-94:1H NMR(300MHz,CDCl3)δ4.77–4.62(m,1H),3.90–3.75(m,1H),3.74–3.56(m,1H),3.34–3.18(m,1H),2.78(d,J=17.1Hz,1H),2.53–2.43(m,1H),2.42–2.33(m,1H),2.28–2.16(m,1H),1.19(s,3H),1.00(s,3H),0.94(s,3H),0.92(s,3H),0.89(s,3H),0.80(s,3H),0.78(s,3H).ESI-MS:m/z 576.53[M+Na]+。
实施例38
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-吖丁啶(化合物A-95)
参照实施例2的方法,将N,N-二甲基乙二胺替换成杂氮环丁烷,制得化合物A-95:1H NMR(300MHz,CDCl3)δ4.48–3.89(m,4H),3.30–3.14(m,1H),2.81–2.66(m,1H),2.48–2.34(m,1H),2.26–2.07(m,3H),1.14(s,3H),0.97(s,3H),0.95(s,3H),0.91(s,3H),0.86(s,3H),0.75(s,3H),0.74(s,3H).ESI-MS:m/z518.5[M+Na]+。
实施例39
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物A-28)
参照实施例2的方法,将N,N-二甲基乙二胺替换成硫代吗啉-1,1-二氧化物,制得化合物A-28:1H NMR(300MHz,CDCl3)δ7.96–7.86(m,1H),7.81–7.70(m,1H),7.65–7.52(m,2H),4.85–4.73(m,1H),4.37–4.12(m,4H),3.08–2.92(m,4H),2.77(d,J=13.3Hz,1H),2.49(d,J=13.2Hz,1H),2.44–2.32(m,1H),1.20(s,3H),0.97(s,3H),0.90(s,9H),0.86(s,3H),0.79(s,3H).ESI-MS:m/z 720.5[M-H]-。
实施例40
N-(2-(1,1-二氧代硫代吗啉基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-74)
参照实施例13的方法,将3-二甲氨基丙胺替换成4-(2-氨乙基)硫代吗啉-1,1-二氧化物,制得化合物A-74:1H NMR(300MHz,CDCl3)δ6.27–6.11(m,1H),3.48–3.29(m,2H),3.29–3.16(m,1H),3.13–2.91(m,8H),2.82(d,J=13.0Hz,1H),2.60(t,J=5.7Hz,2H),2.47(d,J=13.5Hz,1H),2.43–2.31(m,1H),1.20(s,3H),0.99(s,3H),0.92(s,3H),0.90(s,3H),0.87(s,3H),0.76(s,3H),0.74(s,3H).ESI-MS:m/z 615.5[M-H]-。
实施例41
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-81)
参照实施例13的方法,将3-二甲氨基丙胺替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,制得化合物A-81:1H NMR(300MHz,CDCl3)δ6.05–5.95(m,1H),3.38–3.17(m,3H),3.12–2.90(m,8H),2.81(d,J=12.5Hz,1H),2.59–2.32(m,4H),1.19(s,3H),0.99(s,3H),0.90(s,6H),0.88(s,3H),0.77(s,3H),0.73(s,3H).ESI-MS:m/z 629.5[M-H]-。
实施例42
N-(2-(1,1-二氧代硫代吗啉基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-9)
参照实施例13的方法,将3-二甲氨基丙胺替换成4-(2-氨乙基)硫代吗啉-1,1-二氧化物,制得化合物A-9:1H NMR(300MHz,DMSO-d6)δ13.20(s,1H),7.79–7.69(m,1H),7.69–7.59(m,3H),6.63–6.52(m,1H),4.73–4.60(m,1H),3.29–3.15(m,2H),3.12–2.98(m,4H),2.98–2.87(m,4H),2.83(d,J=15.0Hz,1H),2.62–2.53(m,2H),2.47(d,J=14.2Hz,1H),1.24–1.17(m,3H),0.94(s,6H),0.92(s,6H),0.85(s,3H),0.74(s,3H).ESI-MS:m/z 763.6[M-H]-。
实施例43
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-23)
参照实施例13的方法,将3-二甲氨基丙胺替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,制得化合物A-23:1H NMR(300MHz,methanol-d4)δ7.82–7.74(m,1H),7.74–7.66(m,1H),7.66–7.57(m,2H),6.86–6.77(m,1H),4.80–4.67(m,1H),3.42–3.23(m,2H),3.18–3.07(m,4H),3.07–2.97(m,4H),2.97–2.86(m,1H),2.64–2.49(m,3H),2.31(d,J=12.8Hz,1H),1.28(s,3H),1.03(s,6H),1.00(s,3H),0.95(s,3H),0.94(s,3H),0.81(s,3H).ESI-MS:m/z777.6[M-H]-。
实施例44
N-(3-(1-四氢吡咯基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-80)
参照实施例13的方法,将3-二甲氨基丙胺替换成1-(3-氨基丙基)吡咯烷,制得化合物A-80:1H NMR(300MHz,CDCl3)δ6.22–6.12(m,1H),3.50–3.34(m,1H),3.29–3.15(m,2H),2.87–2.75(m,1H),2.61–2.37(m,8H),1.21(s,3H),1.18(s,3H),0.99(s,3H),0.91(s,3H),0.88(s,3H),0.77(s,3H),0.73(s,3H).ESI-MS:m/z 567.5[M+H]+。
实施例45
N-(3-(4-甲基-1-哌嗪基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-79)
参照实施例13的方法,将3-二甲氨基丙胺替换成1-(3-氨丙基)-4-甲基哌嗪,制得化合物A-79:1H NMR(300MHz,CDCl3)δ6.09–5.96(m,1H),3.41–3.28(m,1H),3.27–3.12(m,2H),2.86–2.72(m,1H),2.65–2.31(m,10H),2.28(s,3H),2.02–1.79(m,2H),1.18(s,6H),0.98(s,3H),0.88(s,6H),0.76(s,3H),0.72(s,3H).ESI-MS:m/z 596.5[M+H]+。
实施例46
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺)四氢吡咯(化合物A-31)
参照实施例2的方法,将N,N-二甲基乙二胺替换成四氢吡咯,制得化合物A-31:1HNMR(300MHz,methanol-d4)δ7.81–7.65(m,2H),7.65–7.51(m,2H),4.80–4.70(m,1H),3.81–3.44(m,4H),2.86(d,J=15.1Hz,1H),2.52(d,J=13.4Hz,1H),2.37(d,J=13.1Hz,1H),1.27(s,3H),1.03(s,3H),1.01(s,6H),0.95(s,6H),0.85(s,3H).ESI-MS:m/z 656.5[M-H]-。
实施例47
N-(2-(乙酰氨基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-64)
参照实施例13的方法,将3-二甲氨基丙胺替换成N-乙酰基乙二胺,制得化合物A-64:1H NMR(300MHz,CDCl3)δ7.93–7.77(m,1H),7.77–7.62(m,1H),7.60–7.46(m,2H),6.62–6.45(m,1H),6.38–6.21(m,1H),4.82–4.66(m,1H),3.57–3.20(m,4H),2.82(d,J=15.1Hz,1H),2.46(d,J=13.3Hz,1H),2.36(d,J=11.6Hz,1H),1.97(s,3H),1.19(s,3H),0.95(s,3H),0.90(s,12H),0.74(s,3H).ESI-MS:m/z 687.5[M-H]-。
实施例48
N-(2-(乙酰氨基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-65)
参照实施例7的方法,将N-(2-氨基乙基)吗啉替换成N-乙酰基乙二胺,制得化合物A-65:1H NMR(300MHz,CDCl3)δ7.85–7.77(m,1H),7.70–7.63(m,1H),7.62–7.50(m,2H),6.60–6.47(m,1H),6.43–6.34(m,1H),6.33–6.23(m,1H),4.76–4.67(m,1H),4.45(t,J=4.7Hz,2H),3.71–3.58(m,2H),3.49–3.26(m,4H),2.91–2.76(m,1H),2.48(d,J=14.3Hz,1H),2.42–2.32(m,1H),2.03(s,3H),1.96(s,3H),1.21(s,3H),0.97(s,3H),0.96(s,6H),0.93(s,3H),0.91(s,3H),0.75(s,3H).ESI-MS:m/z 796.6[M+Na]+。
实施例49
N-(2-(1-四氢吡咯基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-71)
参照实施例13的方法,将3-二甲氨基丙胺替换成1-(2-氨乙基)吡咯烷,制得化合物A-71:1H NMR(300MHz,CDCl3)δ6.59–6.45(m,1H),3.46–3.17(m,3H),2.89–2.74(m,1H),2.60–2.30(m,7H),1.18(s,6H),0.99(s,3H),0.93(s,3H),0.89(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 553.5[M+H]+。
实施例50
1-甲基-4-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺)哌嗪(化合物A-30)
参照实施例2的方法,将N,N-二甲基乙二胺替换成N-甲基哌嗪,制得化合物A-30:1H NMR(300MHz,methanol-d4)δ7.79–7.72(m,1H),7.72–7.65(m,1H),7.65–7.54(m,2H),4.74(dd,J=10.7,5.1Hz,1H),4.28–3.84(m,4H),3.28–3.12(m,4H),2.89(s,3H),2.84(d,J=12.6Hz,1H),2.57(d,J=13.3Hz,1H),2.38(d,J=12.6Hz,1H),1.27(s,3H),1.00(s,3H),0.99(s,3H),0.97(s,3H),0.95(s,3H),0.93(s,3H),0.85(s,3H).ESI-MS:m/z 687.5[M+H]+。
实施例51
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-(3S)-氨基-四氢吡咯(化合物A-89)
参照实施例2的方法,将N,N-二甲基乙二胺替换成(S)-3-N-苄氧羰基氨基吡咯烷,制得化合物VII-1。
取化合物VII-1(200mg,0.303mmol)溶于四氢呋喃(10mL)中,加入10%钯碳(20mg),氢气氛围下室温搅拌过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=10:1)纯化,得化合物A-89(白色固体,135mg,产率85%):1H NMR(300MHz,CDCl3)δ3.84–3.75(m,1H),3.74–3.66(m,1H),3.66–3.57(m,1H),3.51(p,J=6.0Hz,1H),3.24(td,J=10.6,5.9Hz,2H),2.82–2.69(m,1H),2.48–2.38(m,1H),2.39–2.29(m,1H),2.04(dt,J=12.4,6.6Hz,1H),1.16(s,3H),0.98(s,3H),0.95(s,3H),0.90(s,3H),0.87(s,3H),0.77(s,3H),0.76(s,3H).ESI-MS:m/z 525.5[M+H]+。
实施例52
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-3-羟基-吖丁啶(化合物A-96)
参照实施例2的方法,将N,N-二甲基乙二胺替换成氮杂环丁烷-3-醇,制得化合物A-96:1H NMR(300MHz,CDCl3)δ5.29–5.20(m,1H),3.90–3.72(m,1H),3.72–3.59(m,1H),3.58–3.40(m,2H),3.26–3.04(m,3H),2.13–1.99(m,2H),1.13(s,3H),0.98(s,3H),0.93(s,3H),0.89(s,6H),0.77(s,3H),0.71(s,3H).ESI-MS:m/z 510.5[M-H]-。
实施例53
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-3-甲氧基-吖丁啶(化合物A-99)
参照实施例2的方法,将N,N-二甲基乙二胺替换成3-甲氧基氮杂丁烷,制得化合物A-99:1H NMR(300MHz,CDCl3)δ4.56–4.17(m,2H),4.11(dt,J=9.4,4.9Hz,1H),4.07–3.71(m,2H),3.29(s,3H),3.26–3.16(m,1H),2.80–2.68(m,1H),2.46–2.35(m,1H),2.17–2.08(m,1H),1.14(s,3H),0.98(s,3H),0.95(s,3H),0.91(s,3H),0.86(s,3H),0.76(s,3H),0.75(s,3H).ESI-MS:m/z 548.5[M+Na]+。
实施例55
N-(3β-羟基-齐墩果烷-13(18)-烯-28-酰基)-3-羧基-吖丁啶(化合物A-100)
将化合物VIII-1(500mg,2.485mmol)溶于甲苯(7.5mL)中,依次加入1,8-二氮杂二环十一碳-7-烯(576mg,3.728mmol)和溴化苄(467mg,2.73mmol),室温下搅拌反应4小时。TLC检测反应完全后,加入水(5mL)淬灭,乙酸乙酯(10mL×2)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=6:1)纯化,得化合物VIII-2(无色油状液体,296mg,产率40%)。
将化合物VIII-2(296mg,1.016mmol)溶于二氯甲烷(5mL)中,加入三氟乙酸(1mL),室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,得化合物VIII-3,直接用于下一步。
参照实施例36的方法,将D-脯氨酸苄酯盐酸盐替换成化合物VIII-3,制得化合物A-100:1H NMR(300MHz,CDCl3)δ4.65–4.01(m,4H),3.42–3.30(m,1H),3.24(dd,J=10.3,5.5Hz,1H),2.85–2.65(m,1H),2.51–2.32(m,1H),2.26–2.04(m,1H),1.15(s,3H),0.98(s,3H),0.95(s,3H),0.92(s,3H),0.87(s,3H),0.76(s,3H),0.75(s,3H).ESI-MS:m/z 538.4[M-H]-。
实施例55
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-25)
参照实施例7的方法,将N-(2-氨基乙基)吗啉替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,制得化合物A-25:1H NMR(300MHz,CDCl3)δ7.86–7.76(m,1H),7.70–7.63(m,1H),7.63–7.50(m,2H),6.58–6.46(m,1H),6.11–5.97(m,1H),4.77–4.66(m,1H),4.49–4.38(m,2H),3.69–3.59(m,2H),3.38–3.24(m,2H),3.18–2.94(m,6H),2.84(d,J=15.3Hz,1H),2.68–2.53(m,2H),2.48(d,J=12.8Hz,1H),2.43–2.34(m,1H),2.03(s,3H),1.21(s,3H),0.96(s,9H),0.93(s,3H),0.92(s,3H),0.75(s,3H).ESI-MS:m/z 862.5[M-H]-。
实施例56
N-(3-(1-四氢吡咯基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-22)
参照实施例13的方法,将3-二甲氨基丙胺替换成1-(3-氨基丙基)吡咯烷,制得化合物A-22:1H NMR(300MHz,methanol-d4)δ7.78(d,J=7.4Hz,1H),7.69–7.54(m,2H),7.54–7.44(m,1H),4.82–4.72(m,1H),3.46–3.39(m,2H),3.18(t,J=7.2Hz,2H),2.95(d,J=14.6Hz,1H),2.62(d,J=13.8Hz,1H),2.36–2.26(m,1H),2.14(s,3H),1.30(s,3H),1.06(s,6H),1.05(s,3H),1.03(s,3H),0.99(s,3H),0.84(s,2H).ESI-MS:m/z 713.6[M-H]-。
实施例57
N-(3-(4-甲基-1-哌嗪基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-21)
参照实施例13的方法,将3-二甲胺丙胺替换成1-(3-氨丙基)-4-甲基哌嗪,制得化合物A-21:1H NMR(300MHz,methanol-d4)δ7.84–7.77(m,1H),7.74–7.68(m,1H),7.68–7.59(m,2H),4.78(dd,J=11.0,4.2Hz,1H),3.82–3.43(m,8H),3.42–3.37(m,2H),3.20–3.09(m,2H),3.02(s,3H),2.95(d,J=13.9Hz,1H),2.62(d,J=13.7Hz,1H),2.32(d,J=13.3Hz,1H),1.30(s,3H),1.05(s,3H),1.04(s,3H),1.02(s,3H),0.98(s,3H),0.95(s,3H),0.83(s,3H).ESI-MS:m/z 742.6[M-H]-。
实施例58
N-(2-(1-哌嗪基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-13)
参照实施例7的方法,将N-(2-氨基乙基)吗啉替换成N-氨乙基哌嗪,制得化合物A-13:1H NMR(300MHz,CDCl3)δ7.81(d,J=7.0Hz,1H),7.66(d,J=7.0Hz,1H),7.62–7.51(m,2H),6.57–6.47(m,1H),6.19–6.11(m,1H),4.77–4.67(m,1H),4.49–4.41(m,2H),3.69–3.60(m,2H),3.49–3.28(m,2H),3.25–3.09(m,4H),2.90–2.71(m,5H),2.59–2.35(m,4H),2.03(s,3H),1.21(s,3H),0.97(s,3H),0.96(s,3H),0.95(s,3H),0.93(s,3H),0.90(s,3H),0.75(s,3H).ESI-MS:m/z801.6[M+H]+。
实施例59
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-二甲氨基乙酯(化合物A-35)
取δ-齐墩果酸(δ-OA,2g,4.379mmol)溶于N,N-二甲基甲酰胺(20mL)中,依次加入1,2-二溴乙烷(3.75mL,43.79mmol)、碳酸钾(605mg,4.379mmol)和乙腈(2mL),将反应液升温至50℃,搅拌反应3小时。TLC检测反应完全后,用乙酸乙酯(30mL)和水(10mL)处理反应液,水层用乙酸乙酯(20mL)萃取,合并有机相,水(20mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,得化合物IX-1(白色固体,2.25g,产率91%)。
取化合物IX-1(150mg,0.266mmol)溶于无水N,N-二甲基甲酰胺(8mL)中,依次加入二甲胺盐酸盐(33mg,0.405mmol)和碳酸钾(56mg,0.405mmol),将反应液升温至50℃,搅拌反应。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物IX-2(白色固体,91mg,产率65%)。
将化合物IX-2(91mg,0.172mmol)溶于无水吡啶(8mL)中,加入邻苯二甲酸酐(255mg,1.72mmol)和4-二甲氨基吡啶(21mg,0.172mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(10mL)和水(10mL)处理反应液,水层用二氯甲烷(10mL)萃取,合并有机相,有机相依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物A-35(白色固体,83mg,产率72%):1H NMR(300MHz,CDCl3)δ7.82(d,J=7.2Hz,1H),7.58(d,J=6.6Hz,1H),7.52–7.39(m,2H),4.83–4.74(m,1H),4.41(t,J=5.5Hz,2H),3.11–2.95(m,2H),2.76(d,J=14.6Hz,1H),2.61(s,6H),2.45(d,J=13.7Hz,1H),2.17(d,J=13.2Hz,1H),1.19(s,3H),1.02(s,3H),0.92(s,9H),0.89(s,3H),0.76(s,3H).ESI-MS:m/z 674.5[M-H]-。
实施例60
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(4-吗啉基)乙酯(化合物A-39)
参照实施例59的方法,将二甲胺盐酸盐替换成吗啉,制得化合物A-39:1H NMR(300MHz,CDCl3)δ7.92–7.81(m,1H),7.74–7.63(m,1H),7.58–7.46(m,2H),4.83–4.71(m,1H),4.28(t,J=4.9Hz,2H),3.81–3.68(m,4H),2.81–2.66(m,3H),2.66–2.50(m,4H),2.42(d,J=13.9Hz,1H),2.22–2.11(m,1H),1.17(s,3H),0.96(s,3H),0.90(s,12H),0.74(s,3H).ESI-MS:m/z 716.5[M-H]-。
实施例61
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(1-四氢吡咯基)乙酯(化合物A-40)
参照实施例59的方法,将二甲胺盐酸盐替换成四氢吡咯,制得化合物A-40:1H NMR(300MHz,CDCl3)δ7.79(d,J=7.3Hz,1H),7.52(d,J=6.6Hz,1H),7.47–7.34(m,2H),4.76(dd,J=10.7,3.2Hz,1H),4.55–4.35(m,2H),3.31–3.05(m,6H),2.73(d,J=12.0Hz,1H),2.42(d,J=13.9Hz,1H),2.12(d,J=13.1Hz,1H),2.08–1.96(m,4H),1.16(s,3H),1.02(s,3H),0.90(s,9H),0.86(s,3H),0.74(s,3H).ESI-MS:m/z 700.5[M-H]-。
实施例62
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(1-哌啶基)乙酯(化合物A-38)
参照实施例59的方法,将二甲胺盐酸盐替换成哌啶,制得化合物A-38:1H NMR(300MHz,methanol-d4)δ7.79(d,J=7.3Hz,1H),7.67(d,J=7.2Hz,1H),7.59(t,J=7.0Hz,1H),7.49(t,J=7.2Hz,1H),4.81–4.73(m,1H),4.45–4.21(m,3H),2.95–2.84(m,1H),2.80(t,J=5.8Hz,2H),2.74–2.62(m,4H),2.56(d,J=14.6Hz,1H),2.31–2.22(m,1H),1.31(s,3H),1.07(s,6H),1.06(s,6H),1.02(s,3H),0.86(s,3H).ESI-MS:m/z 714.5[M-H]-。
实施例63
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸3-(1-四氢吡咯基)丙酯(化合物A-42)
参照实施例59的方法,将1,2-二溴乙烷替换成1,3-二溴丙烷,二甲胺盐酸盐替换成四氢吡咯,制得化合物A-42:1H NMR(300MHz,CDCl3)δ7.74(d,J=7.3Hz,1H),7.55(d,J=7.0Hz,1H),7.46–7.31(m,2H),4.78–4.69(m,1H),4.24–4.03(m,2H),3.19(s,4H),3.08–2.95(m,2H),2.74(d,J=13.6Hz,1H),2.43(d,J=14.1Hz,1H),2.26–2.01(m,7H),1.17(s,3H),0.99(s,3H),0.89(s,12H),0.74(s,3H).ESI-MS:m/z 714.5[M-H]-。
实施例64
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸3-二甲氨基丙酯(化合物A-43)
参照实施例59的方法,将1,2-二溴乙烷替换成1,3-二溴丙烷,制得化合物A-43:1HNMR(300MHz,methanol-d4)δ7.76(d,J=7.5Hz,1H),7.64–7.53(m,2H),7.50–7.42(m,1H),4.81–4.69(m,1H),4.32–4.14(m,2H),3.18–3.08(m,2H),2.86(s,7H),2.55(d,J=14.3Hz,1H),2.26–2.20(m,1H),2.20–2.08(m,2H),1.29(s,3H),1.04(s,6H),1.02(s,6H),0.98(s,3H),0.83(s,3H).ESI-MS:m/z 690.6[M+H]+。
实施例65
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(4-甲基-1-哌嗪基)乙酯(化合物A-48)
参照实施例7的方法制得化合物III-5。取化合物III-5(345mg,0.500mmol)溶于无水N,N-二甲基甲酰胺(8mL)中,依次加入1,2-二溴乙烷(435μL,5.00mmol)和碳酸钾(70mg,0.500mmol),将反应液升温至50℃,搅拌反应3小时。TLC检测反应完全后,用乙酸乙酯(10mL)和水(10mL)处理反应液,水层用乙酸乙酯(10mL)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=1:1)纯化,得化合物X-1(白色固体,348mg,产率87%)。
取化合物X-1(116mg,0.145mmol)溶于无水N,N-二甲基甲酰胺(8mL)中,依次加入N-甲基哌嗪(33μL,0.291mmol)和三乙胺(41μL,0.291mmol),将反应液升温至50℃,搅拌反应。TLC检测反应完全后,用乙酸乙酯(10mL)和水(10mL)处理反应液,水层用乙酸乙酯(10mL)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物A-48(白色固体,63mg,产率53%):1H NMR(300MHz,CDCl3)δ7.86–7.78(m,1H),7.69–7.63(m,1H),7.63–7.49(m,2H),6.62–6.50(m,1H),4.77–4.67(m,1H),4.45(t,J=4.8Hz,2H),4.28–4.14(m,2H),3.70–3.59(m,2H),2.75(d,J=13.0Hz,1H),2.68–2.33(m,11H),2.29(s,3H),2.21–2.15(m,1H),2.03(s,3H),1.17(s,3H),0.96(s,6H),0.95(s,3H),0.93(s,3H),0.92(s,3H),0.74(s,3H).ESI-MS:m/z 816.7[M+H]+。
实施例66
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(1-哌嗪基)乙酯(化合物A-47)
参照实施例65的方法,将N-甲基哌嗪替换成哌嗪,制得化合物A-47:1H NMR(300MHz,CDCl3)δ7.84–7.79(m,1H),7.69–7.63(m,1H),7.62–7.50(m,2H),6.61–6.50(m,1H),4.77–4.67(m,1H),4.44(t,J=5.0Hz,2H),4.26–4.12(m,2H),3.71–3.60(m,2H),3.25–3.13(m,4H),2.91–2.70(m,5H),2.66(t,J=5.5Hz,2H),2.42(d,J=14.1Hz,1H),2.21–2.11(m,1H),2.03(s,3H),1.18(s,3H),0.97(s,3H),0.96(s,3H),0.95(s,3H),0.91(s,6H),0.74(s,3H).ESI-MS:m/z 802.7[M+H]+。
实施例67
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰基)-吖丁啶(化合物A-106)
参照实施例2的方法,将N,N-二甲基乙二胺替换成杂氮环丁烷,制得化合物A-106:1HNMR(300MHz,CDCl3)δ8.00–7.36(m,4H),4.88–4.64(m,1H),4.34–3.93(m,4H),2.83–2.66(m,1H),2.48–2.33(m,1H),1.15(s,3H),0.93(s,9H),0.85(s,6H),0.77(s,3H).ESI-MS:m/z642.5[M-H]-。
实施例68
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酰基)-3-甲氧基-吖丁啶(化合物A-107)
参照实施例2的方法,将N,N-二甲基乙二胺替换成3-甲氧基氮杂丁烷,制得化合物A-107:1H NMR(300MHz,DMSO-d6)δ13.24(s,1H),7.76–7.68(m,1H),7.66–7.57(m,3H),4.71–4.56(m,1H),4.50–3.58(m,5H),3.19(s,3H),2.79–2.63(m,1H),2.34(d,J=13.5Hz,1H),2.10–1.97(m,1H),1.14(s,3H),0.91(s,3H),0.88(s,9H),0.82(s,3H),0.73(s,3H).ESI-MS:m/z 672.5[M-H]-。
实施例69
N-(2-(1-哌嗪基)乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-72)
参照实施例13的方法,将3-二甲氨基丙胺替换成N-氨乙基哌嗪,制得化合物A-72:1HNMR(300MHz,DMSO-d6)δ9.77–9.47(m,2H),7.71–7.58(m,1H),5.30–5.19(m,1H),3.97–3.58(m,4H),3.52–3.32(m,6H),3.14–2.95(m,3H),2.88–2.76(m,1H),1.09(s,3H),0.89(s,6H),0.87(s,3H),0.85(s,3H),0.67(s,3H),0.66(s,3H).ESI-MS:m/z 568.5[M+H]+。
实施例70
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-三甲基铵基乙酯溴化物(化合物A-45)
参照实施例65的方法,将N-甲基哌嗪替换成三甲胺,制得化合物A-45:1H NMR(300MHz,methanol-d4)δ7.78–7.71(m,2H),7.66–7.59(m,2H),4.76–4.67(m,2H),4.61–4.51(m,2H),4.36(t,J=5.5Hz,2H),3.73(t,J=5.0Hz,2H),3.53(t,J=5.4Hz,2H),3.24(s,9H),2.81(d,J=15.0Hz,1H),2.49(d,J=13.9Hz,1H),2.19(d,J=13.5Hz,1H),1.96(s,4H),1.24(s,3H),0.99(s,3H),0.97(s,3H),0.97(s,3H),0.94(s,3H),0.92(s,3H),0.79(s,3H).ESI-MS:m/z 775.6[M-Br]+。
实施例71
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸3-三甲基铵基丙酯溴化物(化合物A-46)
参照实施例65的方法,将1,2-二溴乙烷替换成1,3-二溴丙烷,N-甲基哌嗪替换成三甲胺,制得化合物A-46:1H NMR(300MHz,methanol-d4)δ7.83–7.76(m,2H),7.71–7.64(m,2H),4.81–4.73(m,1H),4.41(t,J=5.5Hz,2H),4.23(dd,J=11.7,5.9Hz,2H),3.58(t,J=5.5Hz,2H),3.48(dd,J=10.2,6.5Hz,2H),3.23(s,9H),2.86(d,J=14.4Hz,1H),2.56(d,J=14.1Hz,1H),2.30–2.16(m,3H),2.01(s,4H),1.29(s,3H),1.04(s,3H),1.02(s,6H),0.98(s,3H),0.97(s,3H),0.83(s,3H).ESI-MS:m/z 789.6[M-Br]+。
实施例72
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-13(18)-烯-28-酸2-(4-甲基-1-哌嗪基)乙酯(化合物A-37)
参照实施例59的方法,将二甲胺盐酸盐替换成N-甲基哌嗪,制得化合物A-37:1HNMR(300MHz,methanol-d4)δ7.84–7.76(m,1H),7.75–7.68(m,1H),7.68–7.60(m,2H),4.77(dd,J=10.6,5.2Hz,1H),4.52–4.40(m,2H),3.80–3.25(m,10H),3.02(s,3H),2.85(d,J=14.8Hz,1H),2.53(d,J=14.2Hz,1H),2.30–2.22(m,1H),1.28(s,3H),1.03(s,3H),1.02(s,3H),1.01(s,3H),0.99(s,3H),0.95(s,3H),0.83(s,3H).ESI-MS:m/z 731.6[M+H]+。
实施例73
N-(2-(二甲氨基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-1)
取齐墩果酸(OA,5g,0.011mol)溶于无水吡啶(35mL)中,搅拌下缓慢滴加醋酸酐(4mL),滴加完毕后加热回流反应1小时。TLC检测反应完全后,反应液冷却至室温,将其滴入冰水(20mL×2)中,析出大量白色固体,抽滤,滤饼用水洗(10mL×3),正己烷洗(10mL×3),真空干燥,乙醇重结晶,得化合物XI-1(白色固体,4.52g,产率83%)。
取化合物XI-1(150mg,0.301mmol)溶于无水二氯甲烷(8mL)中,搅拌下缓慢滴加草酰氯(130μL,1.504mmol)和N,N-二甲基甲酰胺(1滴),室温反应3小时。TLC检测反应完全后,减压蒸除溶剂,得化合物XI-2(黄色固体,155mg,产率100%)。
将N,N-二甲基乙二胺(66μL,0.602mmol)溶于无水二氯甲烷(5mL)中,搅拌下缓慢滴加化合物XI-2(155mg,0.301mmol)的无水二氯甲烷(5mL)溶液和三乙胺(84μL,0.602mmol),室温反应5小时。TLC检测反应完全后,加入二氯甲烷(10mL)稀释反应液,反应液依次用饱和碳酸氢钠溶液(10mL×3)、水(10mL×3)和饱和食盐水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=100:1~50:1)纯化,得化合物XI-3(白色固体,156mg,产率91%)。
将化合物XI-3(156mg,0.274mmol)悬浮于甲醇(10mL)中,加入氢氧化钾(154mg,2.74mmol),将反应液升温至65℃,反应5小时。TLC检测反应完全后,反应液冷却至室温,减压蒸除溶剂,残余物用乙酸乙酯(20mL)和水(20mL)处理,有机相依次用水(20mL×3)和饱和食盐水(20mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=10:1)纯化,得化合物B-1(白色固体,123mg,产率85%):1H NMR(300MHz,CDCl3)δ6.59–6.45(m,1H),5.35(t,J=3.4Hz,1H),3.44–3.29(m,1H),3.27–3.07(m,2H),2.59–2.46(m,1H),2.37(t,J=6.1Hz,2H),2.23(s,6H),1.16(s,3H),0.99(s,3H),0.91(s,9H),0.79(s,3H),0.78(s,3H).ESI-MS:m/z 527.5[M+H]+。
实施例74
N-(3β-羟基-齐墩果烷-12-烯-28-酰胺)-吗啉(化合物B-2)
参照实施例73的方法,将N,N-二甲基乙二胺替换成吗啉,制得化合物B-2:1H NMR(300MHz,CDCl3)δ5.33–5.21(m,1H),3.76–3.54(m,8H),3.28–3.15(m,1H),3.15–3.03(m,1H),1.16(s,3H),1.00(s,3H),0.95(s,3H),0.92(s,6H),0.80(s,3H),0.75(s,3H).ESI-MS:m/z 526.5[M+H]+。
实施例75
N-(2-(二甲氨基)乙基)-N-甲基-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-3)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N,N,N'-三甲基乙二胺,制得化合物B-3:1H NMR(300MHz,CDCl3)δ5.26(t,J=3.3Hz,1H),3.43(t,J=7.2Hz,2H),3.26–3.17(m,1H),3.16–3.12(m,1H),3.10(s,3H),2.54–2.31(m,3H),2.25(s,6H),1.14(s,3H),0.99(s,3H),0.93(s,3H),0.91(s,3H),0.89(s,3H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z541.6[M+H]+。
实施例76
N-(3-(二甲氨基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-4)
参照实施例73的方法,将N,N-二甲基乙二胺替换成3-二甲氨基丙胺,制得化合物B-4:1H NMR(300MHz,CDCl3)δ7.03–6.96(m,1H),5.33–5.28(m,1H),3.59–3.45(m,1H),3.27–3.15(m,1H),3.08–2.94(m,1H),2.60–2.47(m,1H),2.47–2.26(m,2H),2.23(s,6H),1.15(s,3H),0.99(s,3H),0.91(s,9H),0.78(s,3H),0.76(s,3H).ESI-MS:m/z 563.5[M+Na]+。
实施例77
N-(2-(二乙氨基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-5)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N,N-二乙基乙二胺,制得化合物B-5:1H NMR(300MHz,CDCl3)δ6.63–6.53(m,1H),5.38–5.33(m,1H),3.53–3.41(m,1H),3.28–3.17(m,1H),3.10–2.97(m,1H),2.65–2.39(m,7H),1.17(s,3H),1.04(t,J=7.1Hz,6H),1.01(s,3H),0.92(s,9H),0.80(s,3H),0.78(s,3H).ESI-MS:m/z 577.5[M+Na]+。
实施例78
N-(2-(1-哌啶基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-6)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-(2-氨乙基)哌啶,制得化合物B-6:1H NMR(300MHz,CDCl3)δ6.65–6.55(m,1H),5.43–5.28(m,1H),3.45–3.32(m,1H),3.27–3.08(m,2H),2.57–2.47(m,1H),2.47–2.24(m,6H),1.16(s,3H),0.99(s,3H),0.91(s,9H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z567.5[M+H]+。
实施例79
N-(2-(4-吗啉烷基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-7)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N-(2-氨基乙基)吗啉,制得化合物B-7:1H NMR(300MHz,CDCl3)δ6.54–6.42(m,1H),5.42–5.30(m,1H),3.78–3.62(m,4H),3.50–3.33(m,1H),3.30–3.08(m,2H),2.58–2.49(m,1H),2.49–2.32(m,6H),1.16(s,3H),0.99(s,3H),0.91(s,6H),0.89(s,3H),0.78(s,3H),0.76(s,3H).ESI-MS:m/z 569.5[M+H]+。
实施例80
N-(3-(4-吗啉烷基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-8)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N-(3-氨基丙基)吗啉,制得化合物B-8:1H NMR(300MHz,CDCl3)δ6.30–6.21(m,1H),5.40–5.31(m,1H),3.79–3.66(m,4H),3.51–3.36(m,1H),3.27–3.16(m,1H),3.13–2.98(m,1H),2.61–2.50(m,1H),2.50–2.31(m,6H),1.16(s,3H),0.99(s,3H),0.90(s,9H),0.78(s,3H),0.76(s,3H).ESI-MS:m/z 569.5[M+H]+。
实施例81
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物B-9)
参照实施例73的方法,将N,N-二甲基乙二胺替换成硫代吗啉-1,1-二氧化物,制得化合物B-9:1H NMR(300MHz,CDCl3)δ5.32–5.23(m,1H),4.09(t,J=5.2Hz,4H),3.26–3.14(m,1H),3.11–2.90(m,4H),2.29–2.10(m,1H),1.15(s,3H),0.99(s,3H),0.93(s,3H),0.91(s,3H),0.90(s,3H),0.78(s,3H),0.71(s,3H).ESI-MS:m/z 574.4[M+H]+。
实施例82
N-(2-(1-四氢吡咯基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-10)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-(2-氨乙基)吡咯烷,制得化合物B-10:1H NMR(300MHz,CDCl3)δ6.64–6.52(m,1H),5.37–5.26(m,1H),3.50–3.34(m,1H),3.19(d,J=4.7Hz,1H),2.63–2.44(m,4H),1.14(s,2H),0.97(s,2H),0.89(s,5H),0.76(s,3H).ESI-MS:m/z 553.5[M+H]+。
实施例83
N-(2-(1-哌嗪基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-11)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N-氨乙基哌嗪,制得化合物B-11:1H NMR(300MHz,DMSO-d6)δ9.77–9.47(m,2H),7.71–7.58(m,1H),5.30–5.19(m,1H),3.97–3.58(m,4H),3.52–3.32(m,6H),3.14–2.95(m,3H),2.88–2.76(m,1H),1.09(s,3H),0.89(s,6H),0.87(s,3H),0.85(s,3H),0.67(s,3H),0.66(s,3H).ESI-MS:m/z 568.5[M+H]+。
实施例84
N-(2-(4-甲基-1-哌嗪基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-12)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-(2-氨乙基)-4-甲基哌嗪,制得化合物B-12:1H NMR(300MHz,CDCl3)δ6.55–6.44(m,1H),5.35(s,1H),4.30–4.14(m,1H),3.46–3.31(m,1H),3.28–3.05(m,2H),2.61–2.36(m,10H),2.29(s,3H),1.14(s,3H),0.96(s,3H),0.88(s,9H),0.75(s,3H),0.73(s,3H).ESI-MS:m/z 582.5[M+H]+。
实施例85
N-(2-(1,1-二氧代硫代吗啉基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-13)
取齐墩果酸(OA,200mg,0.438mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(243μL,1.752mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(216mg,0.569mmol),反应1小时后加入化合物4-(2-氨乙基)硫代吗啉-1,1-二氧化物(156mg,0.875mmol),反应液升温至60℃。TLC检测反应完全后,用乙酸乙酯(10mL)和水(5mL)处理反应液,水层用乙酸乙酯(10mL×2)萃取,合并有机层,水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=50:1)纯化,得化合物B-13(白色固体,175mg,产率65%):1H NMR(300MHz,CDCl3)δ6.22(s,1H),5.35(s,1H),3.49(dd,J=13.6,6.2Hz,1H),3.20(d,J=4.8Hz,2H),3.05(s,8H),2.63(s,2H),2.49(d,J=11.0Hz,1H),1.17(s,3H),0.99(s,2H),0.90(s,6H),0.78(s,2H),0.76(s,3H).ESI-MS:m/z 617.5[M+H]+。
实施例86
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(2S)-羧基-四氢吡咯(化合物B-16)
参照实施例73的方法,将N,N-二甲基乙二胺替换成L-脯氨酸苄酯盐酸盐,制得化合物XII-1。
取化合物XII-1(120mg,0.186mmol)溶于四氢呋喃(1mL)和甲醇(1mL)的混合溶液中,加入2N氢氧化钠溶液(1mL),80℃下反应2小时。TLC检测反应完全后,减压蒸除溶剂,用1N盐酸溶液调节pH至弱酸性,二氯甲烷萃取(5mL×2),水洗(5mL×2)有机相,饱和食盐水洗涤(5mL×2),无水硫酸钠干燥,减压蒸除溶剂,残余物用二氯甲烷和乙腈的混合溶剂(5.5mL,v:v=10:1)于超声中处理,析出白色固体,抽滤,滤饼用二氯甲烷和乙腈的混合溶剂(5.5mL,v:v=10:1)洗涤两次,红外下干燥,得化合物B-16(白色固体,88mg,产率85%):1H NMR(300MHz,DMSO-d6)δ5.32–5.24(m,1H),4.66–4.53(m,1H),3.85–3.67(m,1H),3.53(q,J=9.3Hz,1H),3.26–3.06(m,2H),2.40(dd,J=13.0,2.5Hz,1H),1.15(s,3H),0.98(s,3H),0.94(s,3H),0.91(s,3H),0.90(s,3H),0.77(s,3H),0.71(s,3H).ESI-MS:m/z 552.3[M-H]-。
实施例87
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-甲基-哌嗪(化合物B-17)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N-甲基哌嗪,制得化合物B-17:1HNMR(300MHz,CDCl3)δ5.30–5.24(m,1H),3.76–3.58(m,4H),3.26–3.18(m,1H),3.10(d,J=12.3Hz,1H),2.45–2.33(m,4H),2.31(s,3H),1.15(s,3H),1.00(s,3H),0.95(s,3H),0.92(s,3H),0.91(s,3H),0.80(s,3H),0.76(s,3H).ESI-MS:m/z 539.5[M+H]+。
实施例88
N-(2-(4-甲基-1-哌嗪基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-18)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成1-(3-氨丙基)-4-甲基哌嗪,制得化合物B-19:1H NMR(300MHz,CDCl3)δ6.41–6.18(m,1H),5.41–5.27(m,1H),3.54–3.35(m,1H),3.29–3.15(m,1H),3.15–2.99(m,1H),2.70–2.33(m,11H),2.29(s,3H),1.16(s,3H),0.99(s,3H),0.91(s,9H),0.79(s,3H),0.76(s,3H).ESI-MS:m/z596.6[M+H]+。
实施例89
N-(2-(1-四氢吡咯基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-19)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成1-(3-氨基丙基)吡咯烷,制得化合物B-19:1H NMR(300MHz,CDCl3)δ5.63–5.33(m,1H),3.65–3.33(m,4H),3.30–2.98(m,6H),2.75–2.43(m,1H),0.99(s,3H),0.94(s,3H),0.91(s,6H),0.78(s,3H),0.71(s,3H).ESI-MS:m/z 567.5[M+H]+。
实施例90
N-(2-(1,1-二氧代硫代吗啉基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-20)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物制得化合物B-20:1H NMR(300MHz,CDCl3)δ6.10–5.98(m,1H),5.43–5.28(m,1H),3.50–3.33(m,1H),3.30–3.18(m,1H),3.12–2.90(m,9H),2.59–2.42(m,3H),1.17(s,3H),0.99(s,3H),0.91(s,9H),0.79(s,3H),0.76(s,3H).ESI-MS:m/z 631.5[M+H]+。
实施例91
N-(2-(1-哌啶基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-22)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成1-(3-氨基丙基)哌啶,制得化合物B-22:1H NMR(300MHz,DMSO-d6)δ8.82(s,1H),7.39(s,1H),5.22(s,1H),4.22(s,1H),3.43–3.32(m,2H),3.12–3.02(2H),3.01–2.95(s,2H),2.89–2.79(m,2H),1.09(s,3H),0.89(s,6H),0.88(s,3H),0.85(s,3H),0.68(s,3H),0.67(s,3H).ESI-MS:m/z581.5[M+H]+。
实施例92
N-(2-(三甲基铵基)乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺溴化物(化合物B-23)
取齐墩果酸(OA,100mg,0.219mmol)溶于N,N-二甲基甲酰胺(8mL)中,加入三乙胺(122μL,0.876mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU,108mg,0.284mmol),反应1小时后加入化合物I-4(116mg,0.438mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和去离子水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,去离子水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=10:1)纯化,得化合物B-23(白色固体,43mg,产率32%):1H NMR(300MHz,methanol-d4)δ7.75–7.66(m,1H),5.46–5.39(m,1H),3.79–3.54(m,2H),3.47(t,J=6.8Hz,2H),3.30–3.14(m,10H),2.91–2.80(m,1H),1.23(s,3H),1.02(s,3H),1.00(s,6H),0.97(s,3H),0.83(s,3H),0.82(s,3H).ESI-MS:m/z 541.5[M-Br]+。
实施例93
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-哌嗪(化合物B-25)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-苄基哌嗪,制得化合物XIII-1。
取化合物XIII-1(100mg,0.163mmol)溶于四氢呋喃(8mL)中,加入10%钯碳(10mg),氢气氛围下室温搅拌反应过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-25(白色固体,61mg,产率72%):1H NMR(300MHz,DMSO-d6)δ9.28(s,2H),5.15–5.02(m,1H),4.34–4.24(m,1H),3.86–3.60(m,4H),3.09–2.87(m,6H),2.12–1.95(m,1H),1.09(s,3H),0.88(s,9H),0.84(s,3H),0.67(s,3H),0.64(s,3H).ESI-MS:m/z 525.5[M+H]+。
实施例94
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-四氢吡咯(化合物B-26)
参照实施例73的方法,将N,N-二甲基乙二胺替换成四氢吡咯,制得化合物B-26:1HNMR(300MHz,CDCl3)δ7.10–6.85(m,1H),5.44–5.22(m,1H),3.63–3.42(m,1H),3.29–3.13(m,1H),3.12–2.93(m,1H),2.67–2.48(m,2H),2.48–2.34(m,3H),2.27(s,6H),1.15(s,4H),0.99(s,4H),0.91(s,9H),0.78(s,3H),0.76(s,3H).ESI-MS:m/z 541.5[M+H]+。
实施例95
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(3S)-氨基-四氢吡咯(化合物B-27)
参照实施例73的方法,将N,N-二甲基乙二胺替换成(S)-3-N-苄氧羰基氨基吡咯烷制得化合物XIV-1。
取化合物XIV-1(216mg,0.328mmol)溶于四氢呋喃(8mL)中,加入10%钯碳(20mg),氢气氛围下室温搅拌反应过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-27(白色固体,143mg,产率83%):1H NMR(300MHz,CDCl3)δ5.29–5.22(m,1H),3.74–3.61(m,2H),3.61–3.49(m,2H),3.37–3.25(m,1H),3.25–3.07(m,2H),1.14(s,3H),0.98(s,3H),0.94(s,3H),0.89(s,6H),0.77(s,3H),0.72(s,3H).ESI-MS:m/z 525.5[M+H]+。
实施例96
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(3R)-氨基-四氢吡咯(化合物B-28)
参照实施例95的方法,将(S)-3-N-苄氧羰基氨基吡咯烷替换成(R)-3-N-苄氧羰基氨基吡咯烷制得化合物B-28:1H NMR(300MHz,CDCl3)δ5.29–5.20(m,1H),3.90–3.72(m,1H),3.72–3.59(m,1H),3.58–3.40(m,2H),3.26–3.04(m,3H),2.13–1.99(m,2H),1.13(s,3H),0.98(s,3H),0.93(s,3H),0.89(s,6H),0.77(s,3H),0.71(s,3H).ESI-MS:m/z 525.5[M+H]+。
实施例97
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(3S)-羟基-四氢吡咯(化合物B-29)
参照实施例73的方法,将N,N-二甲基乙二胺替换成(S)-3-吡咯烷醇,制得化合物B-29:1H NMR(300MHz,CDCl3)δ5.26(m,1H),4.50–4.36(m,1H),3.75–3.61(m,2H),3.61–3.49(m,2H),3.24–3.09(m,2H),1.13(s,3H),0.97(s,3H),0.93(s,3H),0.89(s,3H),0.88(s,3H),0.76(s,3H),0.72(s,3H).ESI-MS:m/z 548.4[M+Na]+。
实施例98
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(3R)-羟基-四氢吡咯(化合物B-30)
参照实施例73的方法,将N,N-二甲基乙二胺替换成(R)-3-吡咯烷醇,制得化合物B-30:1H NMR(300MHz,CDCl3)δ5.24(m,1H),4.49–4.31(m,1H),3.81–3.57(m,3H),3.56–3.43(m,1H),3.29–3.13(m,1H),3.14–2.95(m,1H),2.56–2.16(m,1H),1.13(s,3H),0.97(s,3H),0.93(s,3H),0.89(s,3H),0.88(s,3H),0.76(s,3H),0.70(s,3H).ESI-MS:m/z 548.4[M+Na]+。
实施例99
3β-羟基-齐墩果烷-12-烯-28-酸2-(1-哌啶基)乙酯(化合物B-31)
取齐墩果酸(OA,5g,10.9mmol)溶于N,N-二甲基甲酰胺(40mL)中,依次加入1,2-二溴乙烷(10.2mL,109mmol)、碳酸钾(1.506g,10.9mmol)和乙腈(4mL),将反应液升温至50℃,搅拌反应3小时。TLC检测反应完全后,用二氯甲烷(100mL)和水(100mL)处理反应液,水层用二氯甲烷(50mL)萃取,合并有机相,水(100mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=10:1)纯化,得化合物XV-1(白色固体,4.44g,产率72%)。
取化合物XV-1(200mg,0.35mmol)溶于无水N,N-二甲基甲酰胺(10mL)中,依次加入哌啶(70μL,0.70mmol)和碳酸钾(48mg,0.35mmol),将反应液升温至50℃,搅拌反应。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物B-31(白色固体,47mg,产率24%):1H NMR(300MHz,CDCl3)δ5.29–5.23(m,1H),4.27–4.09(m,2H),3.26–3.15(m,1H),2.89–2.79(m,1H),2.63(t,J=5.5Hz,2H),2.54–2.42(m,4H),1.13(s,3H),0.98(s,3H),0.92(s,3H),0.90(s,6H),0.78(s,3H),0.73(s,3H).ESI-MS:m/z 568.6[M+H]+。
实施例100
3β-羟基-齐墩果烷-12-烯-28-酸2-(4-吗啉基)乙酯(化合物B-32)
参照实施例99的方法,将哌啶替换成吗啉,制得化合物B-32:1H NMR(300MHz,CDCl3)δ5.30–5.18(m,1H),4.70–4.52(m,2H),4.42–4.11(m,2H),4.11–3.79(m,2H),3.63–3.31(m,2H),3.31–3.08(m,3H),3.04–2.84(m,2H),2.78(d,J=12.5Hz,1H),1.14(s,3H),0.99(s,3H),0.91(s,9H),0.78(s,3H),0.70(s,3H).ESI-MS:m/z 570.6[M+H]+。
实施例101
3β-羟基-齐墩果烷-12-烯-28-酸2-(1-四氢吡咯基)乙酯(化合物B-33)
参照实施例99的方法,将哌啶替换成四氢吡咯,制得化合物B-33:1H NMR(300MHz,CDCl3)δ5.31–5.21(m,1H),4.67–4.48(m,2H),3.90–3.71(m,2H),3.39–3.12(m,3H),2.92–2.72(m,3H),2.35–2.16(m,2H),2.16–2.02(m,2H),2.02–1.92(m,1H),1.91–1.82(m,2H),1.13(s,3H),0.98(s,3H),0.90(s,9H),0.77(s,3H),0.69(s,3H).ESI-MS:m/z 554.6[M+H]+。
实施例102
N-(2-(乙酰氨基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-38)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成N-乙酰基乙二胺,制得化合物XVI-1。
将化合物XVI-1(120mg,0.222mmol)溶于无水吡啶(8mL)中,加入邻苯二甲酸酐(329mg,2.22mmol)和4-二甲氨基吡啶(28mg,0.222mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(20mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-38(白色固体,96mg,产率63%):制得化合物B-38:1H NMR(300MHz,methanol-d4)δ7.79–7.72(m,1H),7.68–7.63(m,1H),7.60–7.52(m,2H),7.35–7.24(m,1H),5.52–5.44(m,1H),5.41–5.34(m,1H),4.77–4.61(m,1H),3.20–3.05(m,1H),2.83–2.65(m,1H),1.21–1.19(m,6H),0.99(s,3H),0.97(s,3H),0.95(s,3H),0.91(s,6H),0.78(s,3H).ESI-MS:m/z 687.5[M-H]-。
实施例103
N-(2-(1-哌啶基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-39)
参照实施例102的方法,将N-乙酰基乙二胺替换成1-(2-氨乙基)哌啶,制得化合物B-39:1H NMR(300MHz,CDCl3)δ7.73–7.61(m,2H),7.50–7.40(m,1H),7.39–7.30(m,1H),7.09(d,J=13.4Hz,1H),5.41–5.25(m,1H),4.79–4.55(m,1H),3.88–3.55(m,3H),3.17–2.76(m,6H),1.17(s,3H),0.99(s,3H),0.95(s,6H),0.89(s,3H),0.87(s,3H),0.77(s,3H).ESI-MS:m/z 715.7[M+H]+。
实施例104
N-(2-(4-吗啉基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-40)
参照实施例102的方法,将N-乙酰基乙二胺替换成N-(2-氨基乙基)吗啉,制得化合物B-40:1H NMR(300MHz,methanol-d4)δ7.74–7.63(m,2H),7.60–7.46(m,2H),5.45–5.32(m,1H),4.74–4.62(m,1H),3.82–3.72(m,4H),3.51–3.38(m,1H),3.38–3.24(m,3H),2.83–2.58(m,7H),1.21(s,3H),1.01(s,3H),0.98(s,3H),0.94(s,6H),0.92(s,3H),0.81(s,3H).ESI-MS:m/z 718.6[M+H]+。
实施例105
N-(2-(1-四氢吡咯基)乙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-41)
参照实施例102的方法,将N-乙酰基乙二胺替换成1-(2-氨乙基)吡咯烷,制得化合物B-41:1H NMR(300MHz,methanol-d4)δ7.82–7.61(m,1H),7.59–7.45(m,2H),7.44–7.32(m,1H),5.48(s,1H),5.33(s,1H),4.72–4.64(m,1H),3.67–3.45(m,2H),3.23–3.10(m,2H),2.94–2.76(m,1H),1.20(s,3H),1.00(s,9H),0.93(s,3H),0.90(s,3H),0.80(s,3H).ESI-MS:m/z 702.6[M+H]+。
实施例106
N-(2-(4-吗啉基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-47)
取齐墩果酸(OA,20g,0.044mol)溶于N,N-二甲基甲酰胺(200mL)中,加入碳酸钾(6g,0.044mol),搅拌下缓慢滴加溴化苄(8mL,0.044mol),滴加完毕后将反应液升温至85℃,反应10小时。TLC检测反应完全后,趁热抽滤,滤饼用热的N,N-二甲基甲酰胺(10mL×3)洗涤,滤液冷却至室温后滴入冰水(100mL×2)中,析出大量白色固体,抽滤,滤饼用水洗(50mL×3),正己烷洗(50mL×3),真空干燥,得化合物III-1(白色固体,22.02g,产率92%)。
将化合物III-1(1g,1.829mmol)溶于无水吡啶(10mL)中,加入邻苯二甲酸酐(2.708g,18.29mmol)和4-二甲氨基吡啶(223mg,1.829mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(30mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物XVII-2(白色固体,925mg,产率73%)。
取化合物XVII-2(150mg,0.216mmol)溶于无水二氯甲烷(6mL)中,依次加入N,N'-二环己基碳酰亚胺(134mg,0.647mmol)、4-二甲氨基吡啶(27mg,0.216mmol)和N-乙酰乙醇胺(30μL,0.324mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=3:1)纯化,得化合物XVII-3(白色固体,159mg,产率95%)。
取化合物XVII-3(159mg,0.204mmol)溶于四氢呋喃(10mL)中,加入10%钯碳(16mg),氢气氛围下室温搅拌反应过夜。TLC检测反应完全后,过滤硅藻土,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=1:1)纯化,得化合物XVII-4(白色固体,90mg,产率64%)
取化合物XVII-4(100mg,0.145mmol)溶于N,N-二甲基甲酰胺(6mL)中,加入三乙胺(40μL,0.290mmol),室温搅拌下加入2-(7-氧化苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(72mg,0.188mmol),反应1小时后加入N-(2-氨基乙基)吗啉(23μL,0.174mmol),反应液升温至50℃。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机层,水(5mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物B-47(白色固体,80mg,产率69%):1H NMR(300MHz,CDCl3)δ7.78(d,J=6.1Hz,1H),7.66(d,J=7.9Hz,1H),7.53–7.42(m,2H),5.34–5.23(m,1H),4.73–4.66(m,1H),4.60–4.49(m,2H),3.52–2.98(m,6H),2.89–2.74(m,1H),1.15(s,3H),0.95(s,3H),0.92(s,9H),0.89(s,3H),0.72(s,3H).ESI-MS:m/z 802.7[M+H]+。
实施例107
N-(2-(4-吗啉基)乙基)-3β-(2-(甲氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-48)
参照实施例106的方法,将N-乙酰乙醇胺替换成甲醇,制得化合物B-48:1H NMR(300MHz,CDCl3)δ7.77–7.65(m,2H),7.59–7.48(m,2H),6.55–6.45(m,1H),5.43–5.35(m,1H),4.75(dd,J=11.4,4.5Hz,1H),3.90(s,3H),3.78–3.68(m,4H),3.48–3.37(m,1H),3.28–3.11(m,1H),2.58–2.39(m,7H),1.18(s,3H),0.97(s,3H),0.96(s,3H),0.92(s,9H),0.78(s,3H).ESI-MS:m/z 753.6[M+Na]+。
实施例108
N-(2-(4-吗啉基)乙基)-3β-(2-(异丙基氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-49)
参照实施例106的方法,将N-乙酰乙醇胺替换成异丙醇,制得化合物B-49:1H NMR(300MHz,CDCl3)δ7.77–7.65(m,2H),7.57–7.48(m,2H),6.59–6.44(m,1H),5.47–5.36(m,1H),5.34–5.20(m,1H),4.77(dd,J=11.8,4.6Hz,1H),3.83–3.64(m,4H),3.53–3.39(m,1H),3.29–3.14(m,1H),2.62–2.38(m,7H),1.37(d,J=6.3Hz,6H),1.20(s,3H),1.00(s,3H),0.98(s,3H),0.94(s,9H),0.80(s,3H).ESI-MS:m/z 759.7[M+H]+。
实施例109
N-(2-(二甲基氨基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-50)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成N,N-二甲基乙二胺,制得化合物B-50:1H NMR(300MHz,CDCl3)δ7.87–7.81(m,1H),7.72–7.65(m,1H),7.65–7.53(m,2H),6.93–6.85(m,1H),6.62–6.50(m,1H),5.49–5.41(m,1H),4.79–4.67(m,1H),4.46(t,J=4.5Hz,2H),3.71–3.63(m,2H),3.60–3.47(m,1H),3.47–3.34(m,1H),3.04–2.92(m,2H),2.75–2.57(m,7H),2.04(s,3H),1.21(s,3H),1.00(s,9H),0.96(s,3H),0.94(s,3H),0.81(s,3H).ESI-MS:m/z 760.6[M+H]+。
实施例110
N-(2-(二甲基氨基)乙基)-3β-(2-(甲氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-51)
参照实施例106的方法,将N-乙酰乙醇胺替换成甲醇,N-(2-氨基乙基)吗啉替换成N,N-二甲基乙二胺,制得化合物B-51:1H NMR(300MHz,CDCl3)δ7.78–7.63(m,2H),7.58–7.48(m,2H),6.60–6.45(m,1H),5.45–5.30(m,1H),4.75(dd,J=11.1,4.4Hz,1H),3.90(s,3H),3.44–3.30(m,1H),3.23–3.08(m,1H),2.60–2.48(m,1H),2.37(t,J=5.9Hz,2H),2.23(s,6H),1.18(s,3H),0.97(s,6H),0.91(s,9H),0.81(s,3H).ESI-MS:m/z 689.5[M+H]+。
实施例111
N-(2-(二甲基氨基)乙基)-3β-(2-(异丙基氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-52)
参照实施例106的方法,将N-乙酰乙醇胺替换成异丙醇,N-(2-氨基乙基)吗啉替换成N,N-二甲基乙二胺,制得化合物B-52:1H NMR(300MHz,CDCl3)δ7.81–7.65(m,2H),7.61–7.47(m,2H),6.66–6.47(m,1H),5.48–5.36(m,1H),5.35–5.22(m,1H),4.79(dd,J=11.6,4.6Hz,1H),3.49–3.31(m,1H),3.29–3.09(m,1H),2.67–2.50(m,1H),2.40(t,J=6.0Hz,2H),2.26(s,6H),1.39(d,6H),1.21(s,3H),1.01(s,6H),0.96(s,3H),0.95(s,6H),0.85(s,3H).ESI-MS:m/z 717.5[M+H]+。
实施例112
N-(2-(1-哌嗪基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-53)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成N-氨乙基哌嗪,制得化合物B-53:1H NMR(300MHz,CDCl3)δ7.85–7.77(m,1H),7.71–7.63(m,1H),7.64–7.49(m,2H),6.62–6.40(m,2H),5.47–5.31(m,1H),4.78–4.64(m,1H),4.44(t,J=4.9Hz,2H),3.74–3.58(m,2H),3.52–3.39(m,1H),3.24–3.11(m,1H),2.99–2.87(m,3H),2.64–2.38(m,6H),2.31(2,3H),2.07–1.99(m,3H),1.18(s,3H),0.97(s,9H),0.92(s,6H),0.79(s,3H).ESI-MS:m/z801.8[M+H]+。
实施例113
N-(2-(4-甲基-1-哌嗪基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-54)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)-4-甲基哌嗪,制得化合物B-54:1H NMR(300MHz,CDCl3)δ7.78(d,J=6.1Hz,1H),7.66(d,J=7.9Hz,1H),7.53–7.42(m,2H),5.34–5.23(m,1H),4.73–4.66(m,1H),4.60–4.49(m,2H),3.52–2.98(m,6H),2.89–2.74(m,1H),1.15(s,3H),0.95(s,3H),0.92(s,9H),0.89(s,3H),0.72(s,3H).ESI-MS:m/z 816.7[M+H]+。
实施例114
N-(2-(三甲基铵基)乙基)-3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺溴化物(化合物B-55)
参照实施例107的方法,将N-(2-氨基乙基)吗啉替换成化合物I-4,制得化合物B-55:1H NMR(300MHz,methanol-d4)δ7.84–7.74(m,2H),7.72–7.64(m,2H),5.45–5.39(m,1H),4.80–4.70(m,1H),4.40(t,J=5.5Hz,2H),3.77–3.61(m,2H),3.58(t,J=5.4Hz,2H),3.46(t,J=6.9Hz,2H),3.24(s,9H),2.87(d,J=9.7Hz,1H),2.25–2.11(m,1H),2.00(s,5H),1.26(s,3H),1.07(s,3H),1.02(s,3H),1.01(s,3H),0.98(s,6H),0.86(s,3H).ESI-MS:m/z774.6[M-Br]+。
实施例115
N-(3-(二甲基氨基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-59)
参照实施例102的方法,将N-乙酰基乙二胺替换成3-二甲氨基丙胺,制得化合物B-59:1H NMR(300MHz,CDCl3)δ7.75–7.54(m,2H),7.52–7.30(m,2H),6.97–6.78(m,1H),5.45–5.29(m,1H),4.76–4.62(m,1H),3.92–3.78(m,1H),3.51–3.36(m,1H),3.31–3.14(m,1H),3.07–2.84(m,1H),2.72(s,6H),1.14(s,3H),0.98(s,3H),0.92(s,6H),0.88(s,6H),0.73(s,3H).ESI-MS:m/z 689.7[M+H]+。
实施例116
N-(3-(4-吗啉基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-60)
参照实施例102的方法,将N-乙酰基乙二胺替换成N-(3-氨丙基)吗啉,制得化合物B-60:1H NMR(300MHz,CDCl3)δ7.82–7.67(m,1H),7.69–7.56(m,1H),7.55–7.36(m,2H),6.54–6.35(m,2H),5.51–5.24(m,1H),4.95–4.60(m,1H),4.04–3.77(m,4H),3.54–3.34(m,1H),3.24–3.03(m,1H),2.91–2.55(m,6H),1.15(s,3H),0.98(s,3H),0.91(s,3H),0.89(s,3H),0.87(s,3H),0.74(s,3H).ESI-MS:m/z 731.7[M+H]+。
实施例117
N-(3-(4-甲基-1-哌嗪基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-61)
参照实施例102的方法,将N-乙酰基乙二胺替换成1-(3-氨丙基)-4-甲基哌嗪,制得化合物B-61:1H NMR(300MHz,CDCl3)δ7.77–7.60(m,2H),7.60–7.37(m,2H),6.60–6.19(m,3H),5.44–5.34(m,1H),4.79–4.57(m,1H),3.57–3.33(m,1H),3.27–3.04(m,8H),2.84–2.72(m,2H),1.19–1.15(m,3H),0.96(s,3H),0.92(s,3H),0.90(s,6H),0.74(s,3H).ESI-MS:m/z744.7[M+H]+。
实施例118
N-(3-(1-四氢吡咯基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-62)
参照实施例102的方法,将N-乙酰基乙二胺替换成1-(3-氨基丙基)吡咯烷,制得化合物B-62:1H NMR(300MHz,CDCl3)δ7.70–7.54(m,2H),7.46–7.38(m,1H),7.36–7.30(m,1H),6.99–6.88(m,1H),5.39–5.27(m,1H),4.76–4.60(m,1H),3.52–3.37(m,1H),3.32–2.91(m,7H),2.81–2.65(m,1H),1.13(s,3H),0.99(s,3H),0.93(s,6H),0.88(s,6H),0.73(s,3H).ESI-MS:m/z 715.7[M+H]+。
实施例119
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-63)
参照实施例102的方法,将N-乙酰基乙二胺替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,制得化合物B-63:1H NMR(300MHz,CDCl3)δ7.90–7.78(m,1H),7.75–7.65(m,1H),7.59–7.50(m,2H),6.17–6.02(m,1H),5.40–5.34(m,1H),5.32–5.24(m,1H),4.83–4.62(m,1H),3.53–3.33(m,1H),3.16–2.96(m,8H),2.62–2.42(m,3H),1.17(s,3H),0.96(s,3H),0.91(s,12H),0.76(s,3H).ESI-MS:m/z 779.7[M+H]+。
实施例120
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-65)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,制得化合物B-65:1H NMR(300MHz,CDCl3)δ7.84–7.77(m,1H),7.69–7.63(m,1H),7.62–7.50(m,2H),6.56–6.46(m,1H),6.05–5.96(m,1H),5.40–5.33(m,1H),4.74–4.65(m,1H),4.44(t,J=4.9Hz,2H),3.69–3.58(m,2H),3.42(dd,J=13.3,6.5Hz,1H),3.10–2.93(m,8H),2.58–2.45(m,3H),2.02(s,4H),1.19(s,3H),0.97(s,9H),0.91(s,6H),0.78(s,3H).ESI-MS:m/z 866.6[M+Na]+。
实施例121
N-(2-(1-哌啶基)乙基)-3β-(2-(甲氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-67)
参照实施例106的方法,将N-乙酰乙醇胺替换成甲醇,N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)哌啶,制得化合物B-67:1H NMR(300MHz,CDCl3)δ7.77–7.64(m,2H),7.58–7.48(m,2H),6.68–6.58(m,1H),5.42–5.34(m,1H),4.75(dd,J=11.3,4.4Hz,1H),3.90(s,3H),3.46–3.32(m,1H),3.27–3.09(m,1H),2.59–2.48(m,1H),2.48–2.28(m,6H),1.18(s,3H),0.96(s,6H),0.92(s,9H),0.79(s,3H).ESI-MS:m/z 729.6[M+H]+。
实施例122
N-(2-(1-哌啶基)乙基)-3β-(2-(异丙基氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-68)
参照实施例106的方法,将N-乙酰乙醇胺替换成异丙醇,N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)哌啶,制得化合物B-68:1H NMR(300MHz,CDCl3)δ7.76–7.62(m,2H),7.56–7.44(m,2H),6.67–6.57(m,1H),5.43–5.34(m,1H),5.32–5.16(m,1H),4.75(dd,J=11.7,4.5Hz,1H),3.47–3.31(m,1H),3.25–3.10(m,1H),2.59–2.47(m,1H),2.47–2.27(m,6H),1.35(d,J=6.2Hz,6H),1.17(s,3H),0.98(s,3H),0.96(s,3H),0.93(s,3H),0.92(s,6H),0.79(s,3H).ESI-MS:m/z757.6[M+H]+。
实施例123
N-(2-(1-哌啶基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-69)
参照实施例106的方法将N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)哌啶,制得化合物B-69:1H NMR(300MHz,CDCl3)δ7.81(d,J=6.7Hz,1H),7.66(d,J=6.6Hz,1H),7.56(p,J=7.0Hz,2H),7.08–6.93(m,1H),6.59–6.46(m,1H),5.48(s,1H),4.71(t,J=7.8Hz,1H),4.52–4.35(m,2H),3.72–3.35(m,5H),3.25–2.90(m,5H),2.69–2.56(m,1H),2.01(s,3H),1.18(s,3H),0.97(s,9H),0.94(s,3H),0.92(s,3H),0.77(s,3H).ESI-MS:m/z 800.7[M+H]+。
实施例124
N-(2-(1-四氢吡咯基)乙基)-3β-(2-(甲氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-70)
参照实施例106的方法,将N-乙酰乙醇胺替换成甲醇,N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)吡咯烷,制得化合物B-70:1H NMR(300MHz,CDCl3)δ7.77–7.64(m,2H),7.58–7.47(m,2H),6.62–6.52(m,1H),5.40–5.28(m,1H),4.75(dd,J=11.4,4.4Hz,1H),3.90(s,3H),3.50–3.38(m,1H),3.25–3.12(m,1H),2.68–2.41(m,7H),1.81–1.76(m,4H),1.18(s,3H),0.97(s,6H),0.91(s,9H),0.81(s,3H).ESI-MS:m/z 715.5[M+H]+。
实施例125
N-(2-(1-四氢吡咯基)乙基)-3β-(2-(异丙基氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-71)
参照实施例106的方法,将N-乙酰乙醇胺替换成异丙醇,N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)吡咯烷,制得化合物B-71:1H NMR(300MHz,CDCl3)δ7.81–7.60(m,2H),7.59–7.44(m,2H),6.64–6.46(m,1H),5.40–5.31(m,1H),5.30–5.19(m,1H),4.75(dd,J=11.3,4.1Hz,1H),3.53–3.32(m,1H),3.26–3.09(m,1H),2.69–2.35(m,7H),1.81–1.75(m,4H),1.18(s,3H),0.98(s,6H),0.93(s,3H),0.91(s,6H),0.81(s,3H).ESI-MS:m/z 743.6[M+H]+。
实施例126
N-(2-(1-四氢吡咯基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-72)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成1-(2-氨乙基)吡咯烷,制得化合物B-72:1H NMR(300MHz,CDCl3)δ7.85–7.78(m,1H),7.70–7.63(m,1H),7.56(qd,J=7.3,3.6Hz,2H),7.08–6.96(m,1H),6.64–6.48(m,1H),5.52–5.42(m,1H),4.78–4.65(m,1H),4.45(tq,J=12.3,6.5,5.6Hz,2H),3.69–3.59(m,2H),3.58–3.34(m,6H),2.71–2.56(m,1H),2.01(s,3H),1.18(s,3H),0.99(s,3H),0.97(s,6H),0.94(s,3H),0.91(s,3H),0.76(s,3H).ESI-MS:m/z 786.7[M+H]+。
实施例127
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-吗啉(化合物B-73)
参照实施例102的方法,将化合物XVI-1替换成化合物B-2,制得化合物B-73:1HNMR(300MHz,DMSO-d6)δ13.18(s,1H),7.69(s,1H),7.60(s,3H),5.08(s,1H),4.66–4.55(m,1H),3.50(s,8H),2.97–2.88(m,1H),1.10(s,3H),0.89(s,6H),0.85(s,6H),0.80(s,3H),0.65(s,3H).ESI-MS:m/z 672.5[M-H]-。
实施例128
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物B-74)
参照实施例102的方法,将化合物XVI-1替换成化合物B-9,制得化合物B-74:1HNMR(300MHz,DMSO-d6)δ7.71(s,1H),7.58(s,3H),5.12(s,1H),4.62(s,1H),3.94(s,4H),3.15–2.96(m,4H),2.92(s,1H),1.13(s,3H),0.92(s,3H),0.91(s,3H),0.88(s,3H),0.87(s,3H),0.82(s,3H),0.67(s,3H).m/z 720.4[M-H]-。
实施例129
N-(3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-四氢吡咯(化合物B-77)
参照实施例102的方法,将化合物XVI-1替换成化合物B-26,制得化合物B-77:1HNMR(300MHz,DMSO-d6)δ13.20(s,1H),7.71(s,1H),7.63(s,3H),5.11(s,1H),4.62(t,J=7.8Hz,1H),3.70–3.33(m,4H),3.08–2.98(m,1H),1.12(s,3H),0.90(s,6H),0.89(s,6H),0.82(s,3H),0.65(s,3H).ESI-MS:m/z 656.5[M-H]-。
实施例130
N-(3β-(2-甲氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-吗啉(化合物B-78)
参照实施例106的方法,将N-乙酰乙醇胺替换成甲醇,N-(2-氨基乙基)吗啉替换成吗啉,制得化合物B-78:1H NMR(300MHz,CDCl3)δ7.77–7.65(m,2H),7.57–7.48(m,2H),5.34–5.22(m,1H),4.75(dd,J=11.3,4.7Hz,1H),3.89(s,3H),3.76–3.54(m,8H),3.17–3.01(m,1H),1.16(s,3H),0.96(s,6H),0.94(s,3H),0.91(s,6H),0.75(s,3H).ESI-MS:m/z 688.5[M+H]+。
实施例131
N-(3β-(2-异丙基氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-吗啉(化合物B-79)
参照实施例106的方法,将N-乙酰乙醇胺替换成异丙醇,N-(2-氨基乙基)吗啉替换成吗啉,制得化合物B-79:1H NMR(300MHz,CDCl3)δ7.77–7.60(m,2H),7.58–7.42(m,2H),5.37–5.15(m,2H),4.75(dd,J=11.6,4.7Hz,1H),3.84–3.42(m,8H),3.18–3.01(m,1H),1.35(d,J=6.1Hz,6H),1.16(s,3H),0.97(s,3H),0.96(s,3H),0.94(s,3H),0.93(s,3H),0.91(s,3H),0.76(s,3H).ESI-MS:m/z 738.5[M+Na]+。
实施例132
N-(3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-吗啉(化合物B-80)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成吗啉,制得化合物B-80:1HNMR(300MHz,CDCl3)δ7.87–7.75(m,1H),7.72–7.61(m,1H),7.61–7.48(m,2H),6.64–6.50(m,1H),5.34–5.24(m,1H),4.80–4.63(m,1H),4.53–4.33(m,2H),3.80–3.41(m,9H),3.20–2.99(m,1H),2.32–2.08(m,1H),2.05(s,3H),1.16(s,3H),0.97(s,9H),0.94(s,3H),0.91(s,3H),0.76(s,3H).ESI-MS:m/z781.7[M+Na]+。
实施例133
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-(1-哌啶基)乙酯(化合物B-87)
参照实施例102的方法,将化合物XVI-1替换成化合物B-31,制得化合物B-87:1HNMR(300MHz,CDCl3)δ7.78(d,J=6.1Hz,1H),7.66(d,J=7.9Hz,1H),7.53–7.42(m,2H),5.34–5.23(m,1H),4.73–4.66(m,1H),4.60–4.49(m,2H),3.52–2.98(m,6H),2.89–2.74(m,1H),1.15(s,3H),0.95(s,3H),0.92(s,9H),0.89(s,3H),0.72(s,3H).ESI-MS:m/z 717.6[M+H]+。
实施例134
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-(4-吗啉基)乙酯(化合物B-88)
参照实施例102的方法,将化合物XVI-1替换成化合物B-32,制得化合物B-88:1HNMR(300MHz,CDCl3)δ7.88–7.79(m,1H),7.71–7.63(m,1H),7.56–7.46(m,2H),5.31–5.24(m,1H),4.76(dd,J=11.5,4.3Hz,1H),4.35–4.22(m,2H),3.88–3.75(m,4H),2.91–2.78(m,3H),2.77–2.62(m,4H),1.15(s,3H),0.97(s,3H),0.93(s,3H),0.92(s,3H),0.91(s,3H),0.90(s,3H),0.73(s,3H).ESI-MS:m/z 716.5[M+H]+。
实施例135
3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-(1-四氢吡咯基)乙酯(化合物B-89)
参照实施例102的方法,将化合物XVI-1替换成化合物B-33,制得化合物B-89:1HNMR(300MHz,CDCl3)δ7.76(d,J=7.3Hz,1H),7.59(d,J=7.5Hz,1H),7.50–7.35(m,2H),5.33–5.25(m,1H),4.79–4.67(m,1H),4.52–4.42(m,2H),3.34–3.11(m,6H),2.91–2.76(m,1H),1.15(s,4H),0.98(s,2H),0.96–0.90(m,9H),0.89(s,3H),0.72(s,3H).ESI-MS:m/z702.5[M+H]+。
实施例136
3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-(4-吗啉基)乙酯(化合物B-93)
参照实施例106的方法制得化合物XVII-4,取化合物XVII-4(300mg,0.435mmol)溶于N,N-二甲基甲酰胺(8mL)中,依次加入1,2-二溴乙烷(375μL,4.348mmol)、碳酸钾(60mg,0.435mmol),将反应液升温至50℃,搅拌反应3小时。TLC检测反应完全后,用二氯甲烷(8mL)稀释反应液,水洗(8mL)反应液,水层用二氯甲烷(8mL)萃取,合并有机相,水(8mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=2:1)纯化,得化合物XVIII-1(白色固体,331mg,产率96%)。
取化合物XVIII-1(200mg,0.251mmol)溶于无水N,N-二甲基甲酰胺(10mL)中,依次加入吗啉(45μL,0.52mmol)和碳酸钾(48mg,0.35mmol),将反应液升温至50℃,搅拌反应。TLC检测反应完全后,用二氯甲烷(10mL)和水(5mL)处理反应液,水层用二氯甲烷(10mL×2)萃取,合并有机相,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=30:1)纯化,得化合物B-93(白色固体,97mg,产率48%):1H NMR(300MHz,CDCl3)δ7.88–7.76(m,1H),7.71–7.63(m,1H),7.62–7.49(m,2H),6.62–6.51(m,1H),5.37–5.18(m,1H),4.86–4.59(m,1H),4.52–4.36(m,2H),4.31–4.08(m,2H),3.82–3.58(m,6H),2.99–2.81(m,1H),2.71–2.58(m,2H),2.58–2.44(m,3H),2.02(s,3H),1.16(s,3H),0.97(s,9H),0.93(s,3H),0.91(s,3H),0.76(s,3H).ESI-MS:m/z 803.8[M+H]+。
实施例137
3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-三甲基铵基乙酯溴化物(化合物B-94)
参照实施例136的方法,将吗啉替换成三甲胺的四氢呋喃溶液,制得化合物B-94:1H NMR(300MHz,methanol-d6)δ7.84–7.74(m,2H),7.71–7.63(m,2H),5.37–5.31(m,1H),4.79–4.70(m,1H),4.61–4.49(m,2H),4.41(t,J=5.4Hz,2H),3.86–3.71(m,2H),3.58(t,J=5.4Hz,2H),3.29(s,9H),2.92(d,J=10.1Hz,1H),2.23–2.10(m,1H),2.00(s,5H),1.26(s,3H),1.07(s,3H),1.03(s,3H),1.00(s,3H),0.99(s,6H),0.85(s,3H).ESI-MS:m/z775.7[M-Br]+。
实施例138
3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸3-三甲基铵基丙酯溴化物(化合物B-95)
参照实施例136的方法,将1,2-二溴乙烷替换成1,3-二溴丙烷,吗啉替换成三甲胺,制得化合物B-95:1H NMR(300MHz,methanol-d6)δ7.84–7.75(m,2H),7.72–7.63(m,2H),5.39–5.33(m,1H),4.76(dd,J=10.2,5.8Hz,1H),4.41(t,J=5.5Hz,2H),4.25–4.12(m,2H),3.58(t,J=5.5Hz,2H),3.48(dd,J=11.0,5.7Hz,2H),3.23(s,9H),2.99–2.89(m,1H),2.28–2.16(m,2H),2.16–2.06(m,1H),2.00(s,5H),1.26(s,3H),1.07(s,3H),1.02(s,3H),1.01(s,3H),0.99(s,6H),0.85(s,3H).ESI-MS:m/z 789.6[M-Br]+。
实施例139
3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酸2-(4-甲基-1-哌嗪基)乙酯(化合物B-97)
参照实施例136的方法,将吗啉替换成N-甲基哌嗪,制得化合物B-97:1H NMR(300MHz,CDCl3)δ7.85–7.78(m,1H),7.69–7.63(m,1H),7.62–7.50(m,2H),6.59–6.48(m,1H),5.30–5.23(m,1H),4.77–4.63(m,1H),4.51–4.37(m,2H),4.28–4.04(m,2H),3.73–3.57(m,2H),2.93–2.80(m,1H),2.73–2.38(m,8H),2.34–2.26(m,2H),2.02(s,3H),1.15(s,3H),0.97(s,9H),0.92(s,3H),0.91(s,3H),0.75(s,3H).ESI-MS:m/z 816.8[M+H]+。
实施例140
N-(2-(乙酰氨基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-105)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成N-乙酰基乙二胺,制得化合物B-105:1H NMR(300MHz,CDCl3)δ7.86–7.78(m,1H),7.70–7.63(m,1H),7.57(qt,J=7.3,3.6Hz,2H),6.68–6.52(m,2H),6.42(t,J=4.8Hz,1H),5.42(s,1H),4.77–4.64(m,1H),4.44(t,J=4.8Hz,2H),3.71–3.57(m,2H),3.54–3.16(m,4H),2.62–2.51(m,1H),2.02(s,3H),1.97(s,3H),1.18(s,3H),0.97(s,9H),0.92(s,6H),0.77(s,3H).ESI-MS:m/z 796.7[M+Na]+。
实施例141
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-吖丁啶(化合物B-106)
参照实施例73的方法,将N,N-二甲基乙二胺替换成杂氮环丁烷,制得化合物B-106:1H NMR(300MHz,CDCl3)δ5.24(t,J=3.2Hz,1H),4.50–3.83(m,4H),3.29–3.12(m,1H),2.85(dd,J=13.4,3.5Hz,1H),2.21(t d,J=7.5Hz,2H),1.12(s,3H),0.98(s,3H),0.92(s,3H),0.91(s,3H),0.89(s,3H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z 518.4[M+Na]+。
实施例142
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-3-羟基-吖丁啶(化合物B-107)
参照实施例73的方法,将N,N-二甲基乙二胺替换成氮杂环丁烷-3-醇,制得化合物B-107:1H NMR(300MHz,CDCl3)δ5.25(m,1H),4.68–4.53(m,1H),4.49–4.20(m,2H),4.14–3.77(m,2H),3.28–3.12(m,1H),2.87–2.77(m,1H),1.13(s,3H),0.98(s,3H),0.92(s,3H),0.90(s,6H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z510.4[M-H]-。
实施例143
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-110)
参照实施例73的方法,将N,N-二甲基乙二胺替换成3-甲氧基氮杂丁烷,制得化合物B-110:1H NMR(300MHz,CDCl3)δ5.28–5.21(m,1H),4.55–3.75(m,5H),3.28(s,3H),3.25–3.13(m,1H),2.90–2.78(m,1H),1.12(s,3H),0.98(s,3H),0.92(s,3H),0.90(s,3H),0.89(s,3H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z 548.5[M+Na]+。
实施例144
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-3-羧基-吖丁啶(化合物B-111)
参照实施例86的方法,将L-脯氨酸苄酯盐酸盐替换成化合物VIII-3,制得化合物B-111:1H NMR(300MHz,CDCl3)δ5.34–5.16(m,1H),4.71–4.02(m,4H),3.40–3.28(m,1H),3.28–3.17(m,1H),2.94–2.71(m,1H),1.13(s,3H),0.99(s,3H),0.92(s,3H),0.90(s,6H),0.79(s,3H),0.75(s,3H).ESI-MS:m/z 538.4[M-H]-。
实施例145
N-(2-(1,1-二氧代硫代吗啉基)乙基)-3β-(2-(2-乙酰氨基)乙氧酰基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-118)
参照实施例106的方法,将N-(2-氨基乙基)吗啉替换成4-(2-氨乙基)硫代吗啉-1,1-二氧化物,制得化合物B-118:1H NMR(300MHz,CDCl3)δ7.81(d,J=6.9Hz,1H),7.66(d,J=6.7Hz,1H),7.62–7.51(m,2H),6.58–6.47(m,1H),6.27–6.12(m,1H),5.40–5.33(m,1H),4.77–4.66(m,1H),4.48–4.38(m,2H),3.69–3.60(m,2H),3.56–3.43(m,1H),3.23–3.01(m,9H),2.69–2.58(m,2H),2.57–2.45(m,1H),1.19(s,3H),0.98(s,9H),0.92(s,3H),0.91(s,3H),0.79(s,3H).ESI-MS:m/z 872.7[M+Na]+。
实施例146
N-(3-(1-哌啶基)丙基)-3β-(2-羧基苯甲酰基)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-119)
参照实施例102的方法,将N-乙酰基乙二胺替换成1-(3-氨基丙基)哌啶,制得化合物B-119:1H NMR(300MHz,DMSO-d6)δ7.70(s,1H),7.55(s,2H),7.31(s,1H),5.22(s,1H),4.61(s,1H),3.30(s,3H),3.04(s,3H),2.80(s,2H),1.12(s,3H),1.05(s,3H),0.92(s,3H),0.90(s,3H),0.88(s,3H),0.82(s,3H),0.68(s,3H).ESI-MS:m/z 727.6[M-H]-。
实施例147
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-(2R)-羧基-四氢吡咯(化合物B-120)
参照实施例86的方法,将L-脯氨酸苄酯盐酸盐替换成D-脯氨酸苄酯盐酸盐,制得化合物B-120:1H NMR(300MHz,DMSO-d6)δ5.26(m,1H),4.64–4.56(m,1H),3.84–3.73(m,1H),3.73–3.61(m,1H),3.26–3.15(m,1H),3.12–2.98(m,1H),2.41–2.26(m,1H),1.15(s,3H),0.98(s,3H),0.93(s,3H),0.91(s,3H),0.89(s,3H),0.77(s,3H),0.72(s,3H).ESI-MS:m/z552.4[M-H]-。
实施例148
N-(2-(N,N-二羟乙基)氨基乙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-76)
参照实施例13的方法,将3-二甲氨基丙胺替换成N,N-双(2-羟乙基)乙二胺,制得化合物A-76:1H NMR(300MHz,DMSO-d6)δ6.61–6.53(m,1H),4.42–4.32(m,2H),4.30(d,J=5.0Hz,1H),3.49–3.38(m,4H),3.27–3.16(m,1H),3.15–2.96(m,2H),2.85–2.72(m,1H),2.61–2.54(m,4H),2.43(d,J=14.1Hz,1H),2.25–2.15(m,1H),1.15(s,3H),0.91(s,3H),0.90(s,6H),0.85(s,3H),0.72(s,3H),0.69(s,3H).ESI-MS:m/z 587.5[M+H]+。
实施例149
N-(2-(N,N-二羟乙基)氨基乙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺(化合物B-15)
参照实施例85的方法,将4-(2-氨乙基)硫代吗啉-1,1-二氧化物替换成N,N-双(2-羟乙基)乙二胺,制得化合物B-15:1H NMR(300MHz,DMSO-d6)δ7.14–7.05(m,1H),5.27–5.22(m,1H),4.45–4.33(m,2H),4.29(d,J=5.1Hz,1H),3.49–3.39(m,4H),3.23–3.11(m,1H),3.07–2.92(m,2H),2.80–2.69(m,1H),2.63–2.54(m,4H),1.11(s,3H),0.91(s,3H),0.90(s,6H),0.87(s,3H),0.69(s,6H).ESI-MS:m/z 587.5[M+H]+。
实施例150
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-乙酰氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-108)
参照实施例2的方法,制得化合物II-1。取化合物II-1(150mg,0.300mmol)溶于四氢呋喃(8mL)中,依次加入N,N-二异丙基乙胺(50μL,0.300mmol)和O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸(116mg,0.361mmol),室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯(8mL)溶解,水洗(8mL×2),无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=20:1)纯化,得化合物XIX-1,直接用于下一步。
将化合物XIX-1溶于N,N-二甲基甲酰胺(8mL)中,依次加入4-(3-氨丙基)硫代吗啉-1,1-二氧化物(58mg,0.300mmol)和碳酸钠(32mg,0.300mmol),室温搅拌反应。TLC检测反应完全后,用乙酸乙酯(8mL)稀释反应液,水洗(8mL)反应液,水层用乙酸乙酯(8mL)萃取,合并有机相,水(8mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-108(白色固体,179mg,产率89%):1H NMR(300MHz,CDCl3)δ5.99(t,J=5.8Hz,1H),4.51(dd,J=10.6,5.7Hz,1H),3.34–3.22(m,2H),3.09–2.93(m,8H),2.87–2.76(m,1H),2.57–2.34(m,4H),2.05(s,3H),1.19(s,3H),0.90(s,9H),0.87(s,3H),0.85(s,3H),0.74(s,3H).ESI-MS:m/z 671.5[M-H]-。
实施例151
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(3-羧基丙酰)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-109)
参照实施例13的方法,将3-二甲氨基丙胺替换成4-(3-氨丙基)硫代吗啉-1,1-二氧化物,邻苯二甲酸酐替换成丁二酸酐,制得化合物A-109:1H NMR(300MHz,CDCl3)δ6.06–5.95(m,1H),4.59–4.48(m,1H),3.39–3.18(m,2H),3.13–2.91(m,8H),2.87–2.75(m,1H),2.73–2.58(m,4H),2.59–2.33(m,4H),1.19(s,3H),0.90(s,9H),0.87(s,3H),0.85(s,3H),0.74(s,3H).ESI-MS:m/z 729.5[M-H]-。
实施例152
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(3-吡啶甲酰)氧基-齐墩果烷-13(18)-烯-28-酰胺(化合物A-110)
取化合物A-81(100mg,0.158mmol)溶于无水二氯甲烷(8mL)中,依次加入N,N'-二环己基碳酰亚胺(66mg,0.317mmol)、4-二甲氨基吡啶(20mg,0.158mmol)和烟酸(30mg,0.238mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(8mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物A-110(白色固体,83mg,产率72%):1H NMR(300MHz,methanol-d4)δ5.99(t,J=5.8Hz,1H),4.51(dd,J=10.6,5.7Hz,1H),3.34–3.22(m,2H),3.09–2.93(m,8H),2.87–2.76(m,1H),2.57–2.34(m,4H),2.05(s,3H),1.19(s,3H),0.90(s,9H),0.87(s,3H),0.85(s,3H),0.74(s,3H).ESI-MS:m/z 736.6[M+H]+。
实施例153
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2S-氨基-3-甲基丁酰)氧基-齐墩果烷-13(18)-烯-28-酰胺二盐酸盐(化合物A-111)
取化合物A-81(100mg,0.158mmol)溶于无水二氯甲烷(8mL)中,依次加入N,N'-二环己基碳酰亚胺(66mg,0.317mmol)、4-二甲氨基吡啶(20mg,0.158mmol)和N-Boc-L-缬氨酸(52mg,0.238mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(8mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物XX-1(白色固体,127mg,产率97%)。
将化合物XX-1(127mg,0.158mmol)溶于无水乙醇(10mL)中,通入氯化氢气体30分钟,室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯和甲醇重结晶,得化合物A-111(白色固体,95mg,产率77%):1H NMR(300MHz,methanol-d4)δ4.77–4.69(m,1H),4.00(d,J=3.8Hz,1H),3.34–3.13(m,8H),2.95(d,J=13.9Hz,1H),2.87–2.71(m,2H),2.61(d,J=14.3Hz,1H),2.46–2.37(m,1H),2.37–2.27(m,1H),1.29(s,3H),1.06(s,3H),1.04(s,3H),1.01(s,3H),0.99(s,6H),0.83(s,3H).ESI-MS:m/z 730.6[M+H]+。
实施例154
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-羟基-齐墩果烷-13(18)-烯-28-酰胺盐酸盐(化合物A-112)
将化合物A-81(100mg,0.158mmol)溶于无水乙醇(10mL)中,通入氯化氢气体30分钟,室温搅拌反应。反应完全后减压蒸除溶剂直至剩余2mL,抽滤,滤饼用乙酸乙酯(1mL×2)洗涤,烘干,得化合物A-111(白色固体,52mg,产率49%)1H NMR(300MHz,DMSO-d6)δ6.99–6.91(m,1H),3.90–3.51(m,8H),3.21–3.08(m,4H),3.06–2.97(m,1H),2.77(d,J=13.7Hz,1H),2.42(d,J=13.7Hz,1H),2.21–2.11(m,1H),1.13(s,3H),0.89(s,9H),0.83(s,3H),0.71(s,3H),0.67(s,3H).ESI-MS:m/z 631.5[M+H]+。
实施例155
3β-羟基-齐墩果烷-13(18)-烯-28-酸3-(1,1-二氧代硫代吗啉基)丙酯(化合物A-113)
取化合物II-1(200mg,0.401mmol)溶于N,N-二甲基甲酰胺(8mL)中,依次加入3-溴-1-丙醇(73μL,0.802mmol)和碳酸钾(111mg,0.802mmol),室温搅拌反应。TLC检测反应完全后,用乙酸乙酯(8mL)稀释反应液,水洗(8mL)反应液,水层用乙酸乙酯(8mL)萃取,合并有机相,水(8mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,得化合物XXI-1(白色固体,197mg,产率88%)。
取化合物XXI-1(197mg,0.354mmol)溶于二氯甲烷(8mL)中,加入氯铬酸吡啶盐(153mg,0.707mmol),室温搅拌反应。TLC检测反应完全后,过滤硅藻土,滤液旋干,经硅胶柱层析(石油醚:乙酸乙酯=10:1)纯化,得化合物XXI-2(白色固体,157mg,产率80%)。
将化合物XXI-2(157mg,0.283mmol)和1,1-二氧化硫代吗啉(39mg,0.283mmol)溶于二氯甲烷(8mL)中,室温搅拌1小时后加入三乙酰氧基硼氢化钠(90mg,0.424mmol),室温搅拌反应。TLC检测反应完全后,加入饱和碳酸氢钠溶液(5mL),分液,水(5mL×2)洗有机相,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=3:1)纯化,得化合物XXI-3(白色固体,69mg,产率36%)。
取化合物XXI-3(69mg,0.102mmol)溶于甲醇(5mL)和四氢呋喃(5mL)的混合溶液中,加入氢氧化钾(57mg,1.024mmol),室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯(10mL)溶解,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=3:1)纯化,得化合物A-113(白色固体,45mg,产率69%):1H NMR(300MHz,CDCl3)δ4.21–4.02(m,2H),3.28–3.17(m,1H),3.14–2.89(m,8H),2.74(d,J=11.3Hz,1H),2.57(t,J=7.0Hz,2H),2.43(d,J=14.0Hz,1H),2.22–2.11(m,1H),1.16(s,3H),0.99(s,3H),0.90(s,3H),0.90(s,3H),0.87(s,3H),0.77(s,3H),0.74(s,3H).ESI-MS:m/z 632.5[M+H]+。
实施例156
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-乙酰氧基-齐墩果烷-12-烯-28-酰胺(化合物B-121)
参照实施例73的方法,制得化合物XI-1。取化合物XI-1(150mg,0.300mmol)溶于四氢呋喃(8mL)中,依次加入N,N-二异丙基乙胺(50μL,0.300mmol)和O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸(116mg,0.361mmol),室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯(8mL)溶解,水洗(8mL×2),无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=20:1)纯化,得化合物XXII-1,直接用于下一步。
将化合物XXII-1溶于N,N-二甲基甲酰胺(8mL)中,依次加入4-(3-氨丙基)硫代吗啉-1,1-二氧化物(58mg,0.300mmol)和碳酸钠(32mg,0.300mmol),室温搅拌反应。TLC检测反应完全后,用乙酸乙酯(8mL)稀释反应液,水洗(8mL)反应液,水层用乙酸乙酯(8mL)萃取,合并有机相,水(8mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-121(白色固体,172mg,产率85%):1H NMR(300MHz,CDCl3)δ6.10–5.97(m,1H),5.41–5.33(m,1H),4.54–4.43(m,1H),3.50–3.34(m,1H),3.17–2.92(m,8H),2.63–2.43(m,3H),2.05(s,3H),1.16(s,3H),0.93(s,3H),0.91(s,3H),0.90(s,3H),0.87(s,3H),0.86(s,3H),0.76(s,3H).ESI-MS:m/z673.6[M+H]+。
实施例157
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(3-羧基丙酰)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-122)
将化合物B-20(100mg,0.158mmol)溶于无水吡啶(8mL)中,加入丁二酸酐(159mg,1.585mmol)和4-二甲氨基吡啶(20mg,0.158mmol),反应液升温至115℃搅拌过夜。TLC检测反应完全后,加入二氯甲烷(20mL)稀释反应液,反应液依次用1N稀盐酸(10mL×3)和水(10mL×3)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-122(白色固体,64mg,产率55%):1H NMR(300MHz,CDCl3)δ6.07–5.97(m,1H),5.39–5.33(m,1H),4.59–4.45(m,1H),3.50–3.34(m,1H),3.12–2.90(m,8H),2.74–2.57(m,4H),2.57–2.42(m,4H),1.16(s,3H),0.93(s,3H),0.91(s,3H),0.90(s,3H),0.86(s,6H),0.76(s,3H).ESI-MS:m/z 731.6[M+H]+。
实施例158
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(3-吡啶甲酰)氧基-齐墩果烷-12-烯-28-酰胺(化合物B-123)
取化合物B-20(141mg,0.223mmol)溶于无水二氯甲烷(8mL)中,依次加入N,N'-二环己基碳酰亚胺(184mg,0.894mmol)、4-二甲氨基吡啶(28mg,0.223mmol)和烟酸(55mg,0.447mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(8mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物B-123(白色固体,118mg,产率72%):1H NMR(300MHz,CDCl3)δ9.23(s,1H),8.77(d,J=4.7Hz,1H),8.29(d,J=8.0Hz,1H),7.39(dd,J=8.0,4.9Hz,1H),6.07–5.96(m,1H),5.41–5.33(m,1H),4.83–4.70(m,1H),3.51–3.34(m,1H),3.11–2.92(m,8H),2.59–2.45(m,3H),1.19(s,3H),1.02(s,3H),0.99(s,3H),0.95(s,3H),0.92(s,3H),0.91(s,3H),0.78(s,3H).ESI-MS:m/z736.6[M+H]+。
实施例159
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-(2S-氨基-3-甲基丁酰)氧基-齐墩果烷-12-烯-28-酰胺二盐酸盐(化合物B-124)
取化合物B-20(100mg,0.158mmol)溶于无水二氯甲烷(8mL)中,依次加入N,N'-二环己基碳酰亚胺(66mg,0.317mmol)、4-二甲氨基吡啶(20mg,0.158mmol)和N-Boc-L-缬氨酸(52mg,0.238mmol),室温搅拌反应。TLC检测反应完全后,抽滤,滤液用水(8mL×2)洗涤,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(二氯甲烷:甲醇=20:1)纯化,得化合物XXIII-1(白色固体,125mg,产率95%)。
将化合物XXIII-1(125mg,0.158mmol)溶于无水乙醇(10mL)中,通入氯化氢气体30分钟,室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯打浆,抽滤,滤饼用乙酸乙酯(2ml×2)洗涤,烘干,得化合物B-124(白色固体,110mg,产率91%):1H NMR(300MHz,methanol-d4)δ5.45–5.39(m,1H),4.76–4.65(m,1H),4.00(d,J=3.7Hz,1H),3.64–3.40(m,8H),3.32–3.18(m,1H),3.17–2.94(m,2H),2.93–2.82(m,1H),2.49–2.33(m,1H),1.25(s,3H),1.05(s,3H),1.01(s,6H),1.00(s,3H),0.97(s,3H),0.86(s,3H).ESI-MS:m/z 730.6[M+H]+。
实施例160
N-(3-(1,1-二氧代硫代吗啉基)丙基)-3β-羟基-齐墩果烷-12-烯-28-酰胺盐酸盐(化合物B-125)
将化合物B-20(70mg,0.111mmol)溶于无水乙醇(10mL)中,通入氯化氢气体30分钟,室温搅拌反应。反应完全后减压蒸除溶剂,残余物用乙酸乙酯打浆,抽滤,滤饼用乙酸乙酯(2ml×2)洗涤,烘干,得化合物B-125(白色固体,69mg,产率93%):1H NMR(300MHz,methanol-d4)δ5.47–5.41(m,1H),3.96–3.78(m,4H),3.73–3.60(m,4H),3.46–3.26(m,4H),3.26–3.17(m,1H),2.92–2.82(m,1H),1.25(s,3H),1.04(s,3H),1.03(s,3H),1.01(s,3H),0.99(s,3H),0.85(s,3H),0.84(s,3H).ESI-MS:m/z 631.6[M+H]+。
实施例161
3β-羟基-齐墩果烷-12-烯-28-酸3-(1,1-二氧代硫代吗啉基)丙酯盐酸盐(化合物B-126)
取化合物XI-1(200mg,0.401mmol)溶于N,N-二甲基甲酰胺(8mL)中,依次加入3-溴-1-丙醇(73μL,0.802mmol)和碳酸钾(111mg,0.802mmol),室温搅拌反应。TLC检测反应完全后,用乙酸乙酯(8mL)稀释反应液,水洗(8mL)反应液,水层用乙酸乙酯(8mL)萃取,合并有机相,水(8mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=5:1)纯化,得化合物XXIV-1(白色固体,220mg,产率98%)。
取化合物XXIV-1(220mg,0.395mmol)溶于二氯甲烷(10mL)中,加入氯铬酸吡啶盐(170mg,0.790mmol),室温搅拌反应。TLC检测反应完全后,过滤硅藻土,滤液旋干,经硅胶柱层析(石油醚:乙酸乙酯=4:1)纯化,得化合物XXIV-2(白色固体,164mg,产率75%)。
将化合物XXIV-2(220mg,0.396mmol)和1,1-二氧化硫代吗啉(54mg,0.396mmol)溶于二氯甲烷(8mL)中,室温搅拌1小时后加入三乙酰氧基硼氢化钠(126mg,0.595mmol),室温搅拌反应。TLC检测反应完全后,加入饱和碳酸氢钠溶液(5mL),分液,水(5mL×2)洗有机相,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=3:1)纯化,得化合物XXIV-3(白色固体,131mg,产率49%)。
取化合物XXIV-3(131mg,0.194mmol)溶于甲醇(5mL)和四氢呋喃(5mL)的混合溶液中,加入氢氧化钾(109mg,1.943mmol),室温搅拌反应。TLC检测反应完全后,减压蒸除溶剂,残余物用乙酸乙酯(10mL)溶解,水(10mL×2)洗,无水硫酸钠干燥,过滤,滤液浓缩,经硅胶柱层析(石油醚:乙酸乙酯=2:1)纯化,得化合物XXIV-4(白色固体,75mg,产率61%)。
将化合物XXIV-4(75mg,0.119mmol)溶于无水乙醇(10mL)中,通入氯化氢气体30分钟,室温搅拌反应。反应完全后减压蒸除溶剂,残余物用乙酸乙酯打浆,抽滤,滤饼用乙酸乙酯(2ml×2)洗涤,烘干,得化合物B-126(白色固体,78mg,产率60%):1H NMR(300MHz,methanol-d4)δ5.36–5.27(m,1H),4.16(t,J=6.3Hz,2H),3.28–3.09(m,8H),2.99–2.89(m,1H),2.82–2.71(m,2H),1.23(s,3H),1.03(s,3H),1.01(s,3H),1.00(s,3H),0.97(s,3H),0.84(s,3H),0.83(s,3H).ESI-MS:m/z 654.5[M+Na]+。
实施例162
N-(3β-乙酰氧基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物A-114)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1,1-二氧化硫代吗啉,制得化合物A-114:1H NMR(300MHz,CDCl3)δ4.55–4.46(m,1H),4.36–4.13(m,4H),3.05–2.93(m,4H),2.76(d,J=13.0Hz,1H),2.48(d,J=13.5Hz,1H),2.39(d,J=12.5Hz,1H),2.05(s,3H),1.18(s,3H),0.92(s,3H),0.90(s,3H),0.87(s,3H),0.86(s,3H),0.85(s,3H),0.79(s,3H).ESI-MS:m/z 616.5[M+H]+。
实施例163
N-(3β-(3-吡啶甲酰)氧基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物A-115)
参照实施例152的方法,将化合物A-81替换成化合物A-85,制得化合物A-115:1HNMR(300MHz,CDCl3)δ9.27–9.19(m,1H),8.77(d,J=3.8Hz,1H),8.29(d,J=7.8Hz,1H),7.47–7.34(m,1H),4.85–4.72(m,1H),4.39–4.11(m,4H),3.13–2.90(m,4H),2.78(d,J=13.3Hz,1H),2.49(d,J=13.1Hz,1H),2.43–2.32(m,1H),1.21(s,3H),1.01(s,3H),0.95(s,6H),0.92(s,3H),0.89(s,3H),0.80(s,3H).ESI-MS:m/z 679.5[M+H]+。
实施例164
N-(3β-(3-羧基丙酰)氧基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物A-116)
参照实施例2的方法,将N,N-二甲基乙二胺替换成1,1-二氧化硫代吗啉,邻苯二甲酸酐替换成丁二酸酐,制得化合物A-116:1H NMR(300MHz,CDCl3)δ4.59–4.48(m,1H),4.38–4.12(m,4H),3.06–2.92(m,4H),2.83–2.73(m,1H),2.71–2.57(m,4H),2.48(d,J=13.2Hz,1H),2.38(d,J=12.4Hz,1H),1.18(s,3H),0.91(s,3H),0.90(s,3H),0.86(s,6H),0.85(s,3H),0.79(s,3H).ESI-MS:m/z 674.5[M+H]+。
实施例165
N-(3β-(2S-氨基-3-甲基丁酰)氧基-齐墩果烷-13(18)-烯-28-酰基)-硫代吗啉-1,1-二氧化物盐酸盐(A-117)
参照实施例153的方法,将化合物A-81替换成化合物A-85,制得化合物A-117:1HNMR(300MHz,DMSO-d6)δ8.55–8.28(m,3H),5.61(d,J=8.1Hz,1H),4.63–4.52(m,1H),4.15–3.93(m,4H),3.88(d,J=3.8Hz,1H),3.22–3.01(m,4H),2.71(d,J=11.9Hz,1H),2.38(d,J=12.9Hz,1H),2.31–2.14(m,2H),1.14(s,3H),0.89(s,3H),0.88(s,6H),0.85(s,3H),0.83(s,3H),0.75(s,3H).ESI-MS:m/z 673.6[M+H]+。
实施例166
N-(3β-乙酰氧基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物B-127)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1,1-二氧化硫代吗啉,制得化合物B-127:1H NMR(300MHz,CDCl3)δ5.32–5.25(m,1H),4.53–4.44(m,1H),4.16–4.05(m,4H),3.12–2.90(m,5H),2.21(t,J=13.6Hz,1H),2.04(s,3H),1.14(s,3H),0.93(s,6H),0.91(s,3H),0.86(s,3H),0.85(s,3H),0.71(s,3H).ESI-MS:m/z 616.5[M+H]+。
实施例167
N-(3β-(3-吡啶甲酰)氧基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物B-128)
参照实施例152的方法,将化合物A-81替换成化合物B-9,制得化合物B-128:1HNMR(300MHz,CDCl3)δ9.23(s,1H),8.77(d,J=4.0Hz,1H),8.29(d,J=8.0Hz,1H),7.42–7.35(m,1H),5.32–5.27(m,1H),4.82–4.72(m,1H),4.18–4.02(m,4H),3.14–2.91(m,5H),2.30–2.13(m,1H),1.17(s,3H),1.02(s,3H),0.98(s,3H),0.94(s,6H),0.92(s,3H),0.74(s,3H).ESI-MS:m/z 679.5[M+H]+。
实施例168
N-(3β-(3-羧基丙酰)氧基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物(化合物B-129)
参照实施例127的方法,将化合物B-2替换成化合物B-9,制得化合物B-129:1H NMR(300MHz,DMSO-d6)δ12.19(s,1H),5.14–5.06(m,1H),4.45–4.35(m,1H),4.01–3.84(m,4H),3.15–2.88(m,5H),1.10(s,3H),0.88(s,9H),0.81(s,6H),0.66(s,3H).ESI-MS:m/z 674.5[M+H]+。
实施例169
N-(3β-(2S-氨基-3-甲基丁酰)氧基-齐墩果烷-12-烯-28-酰基)-硫代吗啉-1,1-二氧化物盐酸盐(化合物B-130)
参照实施例159的方法,将化合物B-20替换成化合物B-9,制得化合物B-130:1HNMR(300MHz,DMSO-d6)δ8.53–8.37(m,3H),5.15–5.06(m,1H),4.60–4.50(m,1H),4.02–3.82(m,5H),3.18–2.87(m,5H),1.11(s,3H),1.01(s,3H),0.99(s,3H),0.90(s,3H),0.87(s,6H),0.66(s,3H).ESI-MS:m/z 671.5[M+H]+。
实施例170
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酸3-(4-吗啉基)丙酯(化合物B-131)
参照实施例136的方法,将1,2-二溴乙烷替换成1,3-二溴丙烷,制得化合物B-131:1HNMR(300MHz,CDCl3)δ7.85–7.79(m,1H),7.69–7.63(m,1H),7.62–7.51(m,2H),6.60–6.50(m,1H),5.32–5.26(m,1H),4.75–4.66(m,1H),4.48–4.39(m,2H),4.13–4.01(m,2H),3.75–3.68(m,4H),3.68–3.59(m,2H),2.87(d,J=10.3Hz,1H),2.52–2.31(m,6H),2.02(s,3H),1.15(s,3H),0.97(s,9H),0.93(s,3H),0.91(s,3H),0.75(s,3H).ESI-MS:m/z 817.7[M+H]+。
实施例171
3β-(2-(2-乙酰氨基乙氧酰基)苯甲酰基)氧基-齐墩果烷-12-烯-28-酸3-(1,1-二氧代硫代吗啉基)丙酯(化合物B-132)
参照实施例161的方法,将化合物XI-1替换成化合物XVII-4,制得化合物B-132:1HNMR(300MHz,CDCl3)δ7.89–7.77(m,1H),7.73–7.63(m,1H),7.62–7.50(m,2H),6.60–6.45(m,1H),5.34–5.24(m,1H),4.75–4.64(m,1H),4.52–4.36(m,2H),4.14–4.01(m,2H),3.73–3.54(m,2H),3.02(d,J=13.2Hz,8H),2.86(d,J=14.1Hz,1H),2.65–2.51(m,2H),1.16(s,3H),0.97(s,9H),0.92(s,6H),0.75(s,3H).ESI-MS:m/z 865.6[M+H]+。
实施例172
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-苄基-哌嗪(化合物B-133)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-苄基哌嗪,制得化合物B-133:1H NMR(300MHz,CDCl3)δ7.39–7.27(m,5H),5.28–5.21(m,1H),3.78–3.60(m,4H),3.57(s,2H),3.27–3.16(m,1H),3.14–3.01(m,1H),2.58–2.31(m,4H),2.16–2.02(m,1H),1.13(s,3H),0.99(s,3H),0.92(s,3H),0.90(s,3H),0.89(s,3H),0.78(s,3H),0.71(s,3H).ESI-MS:m/z 615.6[M+H]+。
实施例173
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-环丙基-哌嗪(化合物B-134)
参照实施例73的方法,将N,N-二甲基乙二胺替换成1-环丙基哌嗪,制得化合物B-134:1H NMR(300MHz,CDCl3)δ5.32–5.21(m,1H),3.72–3.44(m,4H),3.27–3.15(m,1H),3.15–3.03(m,1H),2.70–2.45(m,4H),2.19–2.03(m,1H),1.14(s,3H),0.99(s,3H),0.93(s,3H),0.90(s,3H),0.90(s,3H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z 565.6[M+H]+。
实施例174
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-乙基-哌嗪(化合物B-135)
参照实施例73的方法,将N,N-二甲基乙二胺替换成N-乙基哌嗪,制得化合物B-135:1H NMR(300MHz,CDCl3)δ5.32–5.23(m,1H),3.77–3.58(m,4H),3.29–3.16(m,1H),3.16–3.02(m,1H),2.54–2.30(m,6H),2.20–2.03(m,1H),1.14(s,3H),0.99(s,3H),0.93(s,3H),0.90(s,6H),0.78(s,3H),0.74(s,3H).ESI-MS:m/z 553.6[M+H]+。
实施例175
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-氧代-哌啶(化合物B-136)
参照实施例73的方法,将N,N-二甲基乙二胺替换成4-哌啶酮,制得化合物B-136:1H NMR(300MHz,CDCl3)δ5.33–5.26(m,1H),3.98–3.79(m,4H),3.26–3.16(m,1H),3.15–3.04(m,1H),2.56–2.33(m,4H),2.27–2.11(m,1H),1.16(s,3H),0.99(s,3H),0.95(s,3H),0.91(s,3H),0.91(s,3H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z 560.5[M+Na]+。
实施例176
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-4-羟基-哌啶(化合物B-137)
参照实施例73的方法,将N,N-二甲基乙二胺替换成4-羟基哌啶,制得化合物B-137:1H NMR(300MHz,CDCl3)δ5.30–5.23(m,1H),4.18–3.99(m,2H),3.97–3.84(m,1H),3.28–3.01(m,4H),1.14(s,3H),0.99(s,3H),0.93(s,3H),0.90(s,6H),0.78(s,3H),0.75(s,3H).ESI-MS:m/z 540.5[M+H]+。
实施例177
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-3-羟甲基-吖丁啶(化合物B-138)
参照实施例73的方法,将N,N-二甲基乙二胺替换成3-氮杂丁烷甲醇,制得化合物B-138:1H NMR(300MHz,CDCl3)δ5.26(t,J=3.0Hz,1H),4.54–3.82(m,4H),3.81–3.70(m,2H),3.27–3.14(m,1H),2.86(dd,J=13.6,3.1Hz,1H),2.79–2.63(m,1H),1.13(s,3H),0.99(s,3H),0.93(s,3H),0.91(s,3H),0.89(s,3H),0.78(s,3H),0.77(s,3H).ESI-MS:m/z524.5[M-H]-。
实施例178
N-(3β-羟基-齐墩果烷-12-烯-28-酰基)-3-甲氧甲酰基-吖丁啶(化合物B-139)
参照实施例73的方法,将N,N-二甲基乙二胺替换成3-甲酸甲酯氮杂环丁烷盐酸盐,制得化合物B-139:1H NMR(300MHz,CDCl3)δ5.38–5.19(m,1H),4.69–4.00(m,4H),3.75(s,3H),3.42–3.29(m,1H),3.21(dd,J=9.1,4.7Hz,1H),2.82(dd,J=13.8,3.5Hz,1H),1.13(s,3H),0.99(s,3H),0.93(s,3H),0.91(s,3H),0.90(s,3H),0.79(s,3H),0.76(s,3H).ESI-MS:m/z 552.5[M-H]-。
实施例179
N-(3β-(吡啶-3-甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-140)
参照实施例158的方法,将化合物B-20替换成化合物B-110,制得化合物B-140:1HNMR(300MHz,CDCl3)δ9.23(s,1H),8.77(d,J=3.8Hz,1H),8.37–8.23(m,1H),7.39(dd,J=7.9,4.9Hz,1H),5.27(t,J=2.9Hz,1H),4.86–4.70(m,2H),4.44–3.86(m,5H),3.30(s,3H),2.87(dd,J=13.5,3.6Hz,1H),1.15(s,3H),1.02(s,3H),0.99(s,3H),0.95(s,3H),0.93(s,3H),0.90(s,3H),0.78(s,3H).ESI-MS:m/z 631.5[M+H]+。
实施例180
N-(3β-(吡啶-2-甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-141)
参照实施例158的方法,将化合物B-20替换成化合物B-110,烟酸替换成2-吡啶甲酸,制得化合物B-141:1H NMR(300MHz,CDCl3)δ8.83–8.74(m,1H),8.06(d,J=7.8Hz,1H),7.82(td,J=7.7,1.6Hz,1H),7.49–7.40(m,1H),5.27(d,J=2.9Hz,1H),4.93–4.80(m,1H),4.45–3.81(m,5H),3.30(s,3H),2.93–2.79(m,1H),1.15(s,3H),1.04(s,3H),0.99(s,3H),0.96(s,3H),0.93(s,3H),0.90(s,3H),0.78(s,3H).ESI-MS:m/z 631.5[M+H]+。
实施例181
N-(3β-(呋喃-2-甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-142)
参照实施例158的方法,将化合物B-20替换成化合物B-110,烟酸替换成糠酸,制得化合物B-142:1H NMR(300MHz,CDCl3)δ8.06–7.98(m,1H),7.45(t,J=1.7Hz,1H),6.81–6.73(m,1H),5.30(t,J=3.2Hz,1H),4.70(dd,J=9.3,6.8Hz,1H),4.55–3.86(m,5H),3.33(s,3H),2.89(dd,J=13.3,3.2Hz,1H),1.18(s,3H),1.00(s,3H),0.98(s,3H),0.96(s,3H),0.95(s,3H),0.93(s,3H),0.81(s,3H).ESI-MS:m/z 631.5[M+H]+。
实施例182
N-(3β-(6-氟吡啶-2-甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-143)
参照实施例158的方法,将化合物B-20替换成化合物B-110,烟酸替换成2-氟吡啶-6-羧酸,制得化合物B-143:1H NMR(300MHz,CDCl3)δ8.00–7.87(m,2H),7.17–7.09(m,1H),5.30–5.24(m,1H),4.38–3.87(m,5H),3.30(s,3H),2.92–2.81(m,1H),1.15(s,3H),1.03(s,3H),0.98(s,3H),0.95(s,3H),0.93(s,3H),0.90(s,3H),0.78(s,3H).ESI-MS:m/z 649.5[M+H]+。
实施例183
N-(3β-(6-氯吡啶-2-甲酰基)氧基-齐墩果烷-12-烯-28-酰基)-3-甲氧基-吖丁啶(化合物B-144)
参照实施例158的方法,将化合物B-20替换成化合物B-110,烟酸替换成2-氯吡啶-6-羧酸,制得化合物B-144:1H NMR(300MHz,CDCl3)δ7.97(d,J=7.5Hz,1H),7.78(t,J=7.7Hz,1H),7.49(d,J=7.9Hz,1H),5.30–5.24(m,1H),4.88–4.76(m,1H),4.43–3.85(m,5H),3.30(s,3H),2.92–2.81(m,1H),1.15(s,3H),1.02(s,3H),0.98(s,3H),0.94(s,3H),0.93(s,3H),0.90(s,3H),0.78(s,3H).ESI-MS:m/z 665.5[M+H]+。
实施例184
化合物对Huh-7细胞AMPK激动作用的活性评价
采用Western Blot方法检测化合物对Huh-7细胞AMPK的激动活性。
1、细胞系:Huh-7细胞(人源肝癌细胞,购自中国科学院干细胞库),用DMEM完全培养基(含10%胎牛血清和1%streptomycin/penicillin),在37℃含有5%CO2的细胞培养箱中培养。
2、抗体:anti-AMPK(Cell Signaling Technology 2532S);anti-pAMPK(Thr172,Cell Signaling Technology 2535S);GAPDH(arigobio),HRP标记的山羊抗兔IgG二抗,HRP标记的山羊抗小鼠IgG二抗(碧云天)。
3、Western Blot实验:检测化合物对Huh-7细胞AMPK磷酸化水平的影响。
取活细胞比例90%以上的细胞进行实验。在12孔板中,Huh-7细胞按照20万每孔铺板。在37℃含有5%CO2的培养箱中培养24小时,贴壁。在完全培养基条件下给予受试化合物,化合物终浓度均设置为10μM,给药时间为12小时,采用AICAR(100μM)作为阳性对照化合物。随后提取蛋白进行Western Blot检测。具体步骤如下:
蛋白样品制备:弃去原培养液,用1×PBS洗涤3次,弃去PBS,每孔加入100μl RIPAbuffer(1×PBS,1%NP40,0.5%脱氧胆酸钠,0.1%SDS,PMSF等),冰上孵育15min,用细胞刮刀将细胞刮下,吸至新的1.5ml EP管中,4℃,12000g,离心15min,将上清转移至新的1.5mlEP管中,放置于冰上,加入1/5体积的6×loading buffer,95℃金属浴加热10min后离心1min,冻存至-20℃备用。
蛋白定量:将蛋白样品20倍稀释,在96孔板中,依次加入20μl稀释后的蛋白样品,200μl BCA(A液:B液=5:1)试剂,37℃孵育30min,在酶标仪上562nm波长下测定OD值,根据标准曲线计算蛋白浓度。
电泳:灌制SDS-PAGE胶,分离胶浓度为10%,浓缩胶浓度为4%。蛋白样品预先在95℃金属浴加热4min后离心1min,每个样品上样30μg总蛋白,用微量进样器逐个加样。连接电源(注意正负极连接),开始时以60 V恒压电泳,当蛋白样品进入分离胶时将电压调至100V继续恒压电泳。当溴酚蓝到达分离胶底部时,根据蛋白marker的分离情况终止电泳。
转膜:将电泳后的胶轻轻取出,切去不需要的部分,将需要的胶浸入Transferbuffer。准备与胶的大小一致的PVDF膜,用前将PVDF膜用甲醇浸透1min,转移至Transferbuffer中,同时将滤纸放入Transfer buffer中浸透。在转印仪阴极的电极板上依次铺上海绵、滤纸、胶、PVDF膜、滤纸和海绵。每层之间都避免有气泡。接通电源,200mA恒流冰浴转印2.5h。
抗体杂交:转膜结束后,取出PVDF膜用l×TBST清洗1遍,放入预先准备好的封闭液中(含0.1%Tween20的1×TBS配置的5%BSA溶液),室温封闭1h。一抗孵育4℃过夜。第二天(12h后),用1×TBST洗3次,每次10min。二抗孵育:用5%BSA稀释的二抗(1:10000)室温孵育1h,1×TBST洗3次,每次10min。吸去PVDF膜上的多余液体,铺在曝光板上,加入等体积混合的ECL试剂盒液体TanonTM High-sig ECL Western Blotting Peroxide Buffer和TanonTMHigh-sig ECL Western Blotting Luminol/Enhancer Solution,运用Tanon化学发光成像仪,ECL显影,采集免疫反应带。
4.、实验结果:对Western Blot实验结果进行灰度扫描后将阴性对照DMSO的p-AMPK/AMPK比值定义为1,本发明合成的受试化合物p-AMPK/AMPK比值为阴性对照组的相对比值,该数值越大,表明化合物的AMPK激动活性越强,活性数据结果如表1所示。
表1、化合物的AMPK激动活性
(阳性对照AICAR浓度为100μM;受试化合物浓度为10μM)
如表1的实验结果所示,在10μM浓度下,本发明提供的新型齐墩果酸和δ-齐墩果酸的衍生物具有显著的AMPK激动活性。例如,化合物A-9、A-12、A-23、A-25、A-27、A-28、A-68、A-81、A-85、A-108、A-109、A-110、A-112、B-9、B-20、B-63、B-65、B-80、B-94、B-110、B-121、B-122、B-123、B-125等化合物均是强效的AMPK激动剂,且活性显著优于100μM的AICAR以及齐墩果酸和δ-齐墩果酸。其中,化合物A-68的AMPK激动活性(pAMPK/AMPK=5.48)是δ-齐墩果酸活性(pAMPK/AMPK=1.45)的3倍以上。以上实验结果表明,本发明的化合物对AMPK具有显著的激动活性,因而可用于制备具有增强AMPK磷酸化水平活性的AMPK激动剂,并进而可用于制备预防或治疗AMPK介导的疾病的药物。本发明实施例中其他未列举化合物其合成方法均可参考上述实施例,并且对AMPK也同样具有显著的激动活性。
实施例185
化合物对Huh-7细胞AMPK下游信号通路的影响
采用Western Blot方法检测化合物对Huh-7细胞AMPK下游信号通路的影响。
细胞培养条件:Huh-7细胞:DMEM完全培养基(含10%胎牛血清和1%streptomycin/penicillin)在5%CO2的37℃培养箱中培养。
抗体:anti-ACC(CST,3676S);anti-pACC(CST,11818S);anti-mTOR(CST,2983S);anti-pmTOR(CST,Ser2448)。
Western Blot实验:检测化合物对Huh-7细胞AMPK下游信号通路的影响:
取活细胞比例90%以上的细胞进行实验。在12孔板中,将Huh-7细胞按照25万每孔铺板,置于含5%CO2的37℃培养箱中培养,12小时后,弃去原先培养基,加入含有化合物的完全培养基,受试化合物的终浓度均设置为10μM,给药时间为12小时。阳性对照化合物采用AICAR(100μM)。随后提取蛋白进行Western Blot检测,检测pACC/ACC和pmTOR/mTOR的蛋白变化情况。实验结果如图1所示。
实验结果(图1)表明,本发明的化合物均能有效地引起AMPK下游蛋白的变化,且其变化趋势与AMPK激动相关。例如,化合物B-125、A-112、B-122、A-109、B-121、A-108、B-123、A-110、B-20和A-81等均能增加AMPK的磷酸化水平,降低mTOR的磷酸化水平,并同时增加ACC的磷酸化水平。此外,本发明其他化合物均能增加AMPK的磷酸化水平,降低mTOR的磷酸化水平,并同时增加ACC的磷酸化水平。
实施例186
片剂
将实施例41中制得的化合物A-81或者其他实施例的化合物(50g)、羟丙甲基纤维素E(150g)、淀粉(200g)、聚维酮K30适量和硬脂酸镁(1g)混合,制粒,压片。
此外,可以根据药典2015版常规制剂法,将实施例1~183制得的化合物赋予不同的药物辅料制成胶囊剂、散剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、软膏剂、栓剂或贴剂等。
Claims (10)
1.如下式I或式II所示的δ-齐墩果酸衍生物或齐墩果酸衍生物、其药学上可接受的盐或酯或溶剂化物:
R1是H、C1-C5烷基或取代基Y取代的C1-C5烷基,所述取代基Y是OH、C(O)OH、C(O)NH2、NH2、NHC(O)CH3、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
Ra是非取代的或取代基L取代的C1-C5烷基,所述取代基L是一个或两个独立地选自下列的取代基:OH、C(O)OH、NH2、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基或NHC(O)CH(CH3)NHC(O)CH(CH3)NH;
R2是取代基Z取代的C1-C5烷基,所述取代基Z是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
R3是H或C1-C3烷基;
R4是取代基W取代的C1-C5烷基,所述取代基W是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基、二乙醇胺基或乙酰基氨基;
R5是连接在环上任一碳上的H、OH、F、NH2、C1-C3烷基氨基、COOH、C1-C3烷基、C1-C3烷氧基、环烷基氧基或杂环烷基氧基;
Q是CH2、O、NR6、S、SO2、CHR7或化学键;
R6是H、C1-C3烷基、C1-C3烷基酰基、C1-C3烷基磺酰基或取代基P取代的C1-C3烷基,所述取代基P是OH、COOH、NH2或C1-C3烷基氨基;
R7是OH、NH2、COOH、C1-C3烷基氨基、C1-C3烷氧基、环烷基氧基或杂环烷基氧基;
n是0、1或2;
m是0、1或2。
2.根据权利要求1所述的化合物、其药学上可接受的盐或酯或溶剂化物,其特征在于,
R1是H、C1-C5烷基或取代基Y取代的C1-C5烷基,所述取代基Y是OH、C(O)OH、C(O)NH2、NH2、NHC(O)CH3、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
Ra是非取代的或取代基L取代的C1-C5烷基,所述取代基L是一个或两个独立地选自下列的取代基:OH、C(O)OH、NH2、吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基或NHC(O)CH(CH3)NHC(O)CH(CH3)NH;
R2是取代基Z取代的C1-C5烷基,所述取代基Z是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基或二乙醇胺基;
R3是H;
R4是取代基W取代的C1-C5烷基,所述取代基W是吡咯烷-1-基、哌啶-1-基、哌嗪-1-基、4-甲基-哌嗪-1-基、吗啉-4-基、硫代吗啉-1,1-二氧代-4-基、N,N-二甲基氨基、N,N-二乙基氨基、三甲基铵基、二乙醇胺基或乙酰基氨基;
R5是连接在环上任一碳上的H、OH、F、NH2、C1-C3烷基氨基或COOH;
Q是CH2、O、NR6、S、SO2或CHR7;
R6是H、C1-C3烷基、C1-C3烷基酰基、C1-C3烷基磺酰基或取代基P取代的C1-C3烷基,所述取代基P是OH、COOH、NH2或C1-C3烷基氨基;
R7是OH、NH2、COOH或C1-C3烷基氨基;
n是0或1;
m是0或1。
3.根据权利要求1所述的化合物、其药学上可接受的盐或酯或溶剂化物,其特征在于,在所述式II化合物中,当取代基Z是N,N-二甲基氨基或三甲基铵基时,R不是H;当取代基W是乙酰基氨基时,R不是H。
5.一种权利要求1-4任一项所述的化合物、其药学上可接受的盐或酯或溶剂化物在制备具有增强AMPK磷酸化水平活性的AMPK激动剂中的应用。
6.一种权利要求1-4任一项所述的化合物、其药学上可接受的盐或酯或溶剂化物在制备预防或治疗AMPK介导的疾病的药物中的用途。
7.根据权利要6所述的用途,所述AMPK介导的疾病包括代谢性疾病、心脑血管疾病、炎症疾病、自身免疫性疾病、器官纤维化疾病、神经退行性疾病、病原体感染所致的继发性疾病、线粒体功能障碍或紊乱疾病或肿瘤。
8.根据权利要6所述的用途,所述AMPK介导的疾病包括胰岛素抵抗、代谢综合征、1型或2型糖尿病、高脂血症、肥胖症、动脉粥样硬化、心肌缺血、心肌梗死、心律失常、冠心病、高血压、心衰、心肌肥大、心肌炎、糖尿病并发症、非酒精性脂肪肝、非酒精性脂肪性肝炎、酒精性脂肪肝、肝硬化、痛风、中风、脑梗死、肺炎、哮喘、慢性阻塞性肺病、慢性支气管炎、肺气肿、闭塞性细支气管炎、特发性肺纤维化、囊性纤维化肺病、过敏性鼻炎、炎性肠病、多囊肾病、***、***、***性红斑狼疮、类风湿关节炎、脊椎关节炎、骨关节炎、滑膜炎、肌腱炎、血栓闭塞性脉管炎、静脉炎、间歇性跛行、瘢痕瘤、银屑病、鱼鳞癣、大疱性类天疱疮、皮炎、接触性皮炎、胰腺炎、慢性肾炎、膀胱炎、脑膜炎、胃炎、败血症、坏疽性脓皮症、葡萄膜炎、帕金森病、阿尔茨海默病、α-共核蛋白病、抑郁症、多发性硬化症、肌萎缩侧索硬化病、纤维肌痛综合症、神经痛、唐氏综合征、哈勒沃登-施帕病、亨廷顿舞蹈病、威尔逊病、肌无力、肌阵挛、运动不耐受、卡恩斯-赛尔综合征、慢性疲乏综合征、利氏综合征、线粒体肌病-脑病-高乳酸血症、中风综合征、中风样发作、杜氏肌营养不良、贝壳肌营养不良、弗立德希氏共济失调或肿瘤。
9.一种预防或治疗AMPK介导的疾病的药物组合物,其包含如权利要求1~4任一项所述的化合物、其药学上可接受的盐或酯或溶剂化合物作为活性成分和药学上可接受的辅料。
10.根据权利要求8所述的药物组合物,其特征在于,所述药物组合物优选为胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、软膏剂、栓剂或贴剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910572404.0A CN112142818B (zh) | 2019-06-27 | 2019-06-27 | 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 |
PCT/CN2020/093248 WO2020259205A1 (zh) | 2019-06-27 | 2020-05-29 | 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910572404.0A CN112142818B (zh) | 2019-06-27 | 2019-06-27 | 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112142818A true CN112142818A (zh) | 2020-12-29 |
CN112142818B CN112142818B (zh) | 2023-07-21 |
Family
ID=73869046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910572404.0A Active CN112142818B (zh) | 2019-06-27 | 2019-06-27 | 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112142818B (zh) |
WO (1) | WO2020259205A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112110978A (zh) * | 2020-10-13 | 2020-12-22 | 中国药科大学 | δ-齐墩果酸皂苷类化合物及其医药用途 |
CN115873060A (zh) * | 2021-09-28 | 2023-03-31 | 中国医学科学院药物研究所 | 12-o-苯甲酸酯齐墩果酸类化合物及其制备与用途 |
CN117379446A (zh) * | 2023-12-12 | 2024-01-12 | 吉林大学 | 齐墩果酸-28-O-β-D-吡喃葡萄糖苷在制备抗结肠炎药物中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115806580A (zh) * | 2021-09-14 | 2023-03-17 | 中国医学科学院药物研究所 | 12-o-脂肪酸酯齐墩果酸类化合物及其制备方法和用途 |
CN115873061A (zh) * | 2021-09-28 | 2023-03-31 | 中国医学科学院药物研究所 | 齐墩果酸12-o-取代乙酸酯化合物及其制备方法及用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105998032A (zh) * | 2016-06-02 | 2016-10-12 | 贵州医科大学 | 齐墩果酸衍生物及其药物组合物在药物中的应用 |
CN107880093A (zh) * | 2016-09-30 | 2018-04-06 | 中国科学院大连化学物理研究所 | 齐墩果酸类化合物的羧酸酯酶1抑制剂及其应用 |
CN108552175A (zh) * | 2018-05-08 | 2018-09-21 | 广西田园生化股份有限公司 | 齐墩果酸及其衍生物在防治稻飞虱中的应用 |
CN108640964A (zh) * | 2018-06-21 | 2018-10-12 | 昆明理工大学 | 一种三萜-氨基酸衍生物、其制备方法和应用 |
CN109485688A (zh) * | 2017-09-13 | 2019-03-19 | 陈重 | 三萜衍生物及其药物组合物和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1426370A (zh) * | 1973-10-31 | 1976-02-25 |
-
2019
- 2019-06-27 CN CN201910572404.0A patent/CN112142818B/zh active Active
-
2020
- 2020-05-29 WO PCT/CN2020/093248 patent/WO2020259205A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105998032A (zh) * | 2016-06-02 | 2016-10-12 | 贵州医科大学 | 齐墩果酸衍生物及其药物组合物在药物中的应用 |
CN107880093A (zh) * | 2016-09-30 | 2018-04-06 | 中国科学院大连化学物理研究所 | 齐墩果酸类化合物的羧酸酯酶1抑制剂及其应用 |
CN109485688A (zh) * | 2017-09-13 | 2019-03-19 | 陈重 | 三萜衍生物及其药物组合物和应用 |
CN108552175A (zh) * | 2018-05-08 | 2018-09-21 | 广西田园生化股份有限公司 | 齐墩果酸及其衍生物在防治稻飞虱中的应用 |
CN108640964A (zh) * | 2018-06-21 | 2018-10-12 | 昆明理工大学 | 一种三萜-氨基酸衍生物、其制备方法和应用 |
Non-Patent Citations (8)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112110978A (zh) * | 2020-10-13 | 2020-12-22 | 中国药科大学 | δ-齐墩果酸皂苷类化合物及其医药用途 |
CN112110978B (zh) * | 2020-10-13 | 2023-02-28 | 中国药科大学 | δ-齐墩果酸皂苷类化合物及其医药用途 |
CN115873060A (zh) * | 2021-09-28 | 2023-03-31 | 中国医学科学院药物研究所 | 12-o-苯甲酸酯齐墩果酸类化合物及其制备与用途 |
CN117379446A (zh) * | 2023-12-12 | 2024-01-12 | 吉林大学 | 齐墩果酸-28-O-β-D-吡喃葡萄糖苷在制备抗结肠炎药物中的应用 |
CN117379446B (zh) * | 2023-12-12 | 2024-03-15 | 吉林大学 | 齐墩果酸-28-O-β-D-吡喃葡萄糖苷在制备抗结肠炎药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112142818B (zh) | 2023-07-21 |
WO2020259205A1 (zh) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112142818B (zh) | 齐墩果酸和δ-齐墩果酸的衍生物及其医药用途 | |
CN111836798B (zh) | ***的前药、其组合物和用途 | |
KR101799009B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
EP1680418B1 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
KR101828616B1 (ko) | 지방산 퓨마레이트 유도체들 및 그들의 용도 | |
JP6483156B2 (ja) | 糖尿病などの疾患の治療用のピロリジンgpr40モジュレータ | |
JP7493635B2 (ja) | Mgat2阻害活性を有する縮合環誘導体 | |
EP2658851B1 (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
CA2859965A1 (en) | Non-systemic tgr5 agonists | |
EP3138834B1 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
EP3564253A1 (en) | Antidepressant compound and preparation method and application thereof | |
CN101263107A (zh) | 作为二肽基肽酶-iv(dpp-iv)抑制剂的药物组合物 | |
CN110526903B (zh) | 双吲哚马来酰亚胺衍生物及其制备方法和用途 | |
US10717727B2 (en) | Pyridinium compounds | |
CN111205346B (zh) | 齐墩果酸的衍生物及其医药用途 | |
IL117810A (en) | N-transformed metastatic carboxylic compounds, and pharmaceutical preparations containing them for the treatment of infection or neurogenic pain or diabetic neurological disease | |
WO2020103878A1 (zh) | Er蛋白调节剂及其应用 | |
US10723699B2 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
EA021237B1 (ru) | Производные бензамида и их применение в качестве ингибиторов hsp90 | |
CN112028815A (zh) | 吲哚类衍生物及其医药用途 | |
WO2014144836A2 (en) | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors | |
EP3140297A1 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
US6107313A (en) | Dopamine receptor antagonists | |
CN107001240B (zh) | 二肽基酮酰胺化合物及其用于治疗和/或预防脂肪积累的用途 | |
CA2979326C (en) | Substituted imidazol derivative and pharmaceutical compositions thereof useful as analgesic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |